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Abstract
The aim of this project was to develop the stochastic models of tumorigenesis to 
investigate the implications of experimental data on tumour induction in wild type and p53 
deficient mice for tumorigenesis mechanisms. These studies have focused on the 
development of stochastic process models for p53 mediated spontaneous and radiation- 
induced tumorigenesis in mice, in which up to 3 stages are assumed to be required for 
malignant transformation. The stages are conceived as the inactivation of one and both p53 
alleles with a third, genetically unspecified stage which may be composite. The model has 
been used to explore the influence of mutation rate, stage number, and the number of stem 
cells at risk on the kinetics of spontaneous appearance of tumours and tumour multiplicity. 
As expected, tumours tended to occur earlier and the more tumours per mouse tend to be 
acquired with lesser stage number, higher mutation rate and higher stem cell number. 
However, a striking observation was that each of these dependencies was more pronounced 
at lower than higher mutation rate. At high mutation rates, the rate of growth of the earliest 
transformed cell exerted a dominant influence on tumour latency independently of the other 
variables. With the incorporation of radiation effects, i.e. cell killing and mutation 
induction into these models, the studies showed that the dose-tumour-latency and dose- 
tumour-multiplicity relationships strongly depend on the spontaneous mutation rate, stage 
number, and age at exposure. The stage number is most influential at low spontaneous 
mutation rate. The optimal time (age) of irradiation for maximum yield of tumours is 
around the time of birth. The exploration of p53 mediated spontaneous and radiation- 
induced tumorigenesis using these models revealed a fundamental problem in that all such 
models predicted excessively large numbers of tumours in both p53 deficient genotypes. 
Analysis showed that this prediction applied for up to five stages being required for
XIV
malignant transformation in wild type mice. These observations have allowed this category 
of simple multistage model to be rejected.
However, we have found that it is possible to accommodate the experimental data in p53 
deficient mice on a multipath/multistage model in which a p53 mediated pathway coexists 
with one or more p53 independent pathways. The analysis favours at least a 5-stage model 
for the p53 mediated pathways with the p53 independent pathway being the majority route 
of tumorigenesis in wild type mice but the minority route in p53 deficient genotypes. 
However, this model requires the assumption of one or more unknown pathways and does 
not enable age-specific tumour incidence curves to be computed. An alternative version is 
a ‘multi-gate’ model in which tumorigenesis results from a small number of gate-pass 
(enabling) events independently of p53 status. The role of p53 inactivation is as a rate 
modifier which accelerates the gate-pass events. Age-incidence curves can be computed 
and are consistent with experimental observations, for as few as 2 or 3 gate-pass events. 
The model more easily accommodates the data if the p53 second allele experiences a 
higher spontaneous mutation rate than the gate-pass genes. This model implies that wild 
type p53 acts to maintain genetic stability, in accordance with the ‘guardian of the genome’ 
concept, and that p53 inactivation amplifies the rate of tumorigenic mutation by a factor 
which we estimate to be about ten-fold. Experimental studies on genetic stability, and on 
the proportions of tumours in different genotypes whose development is p53 mediated, 
should help to decide between these models.
Competitive development of tumours in two mouse tissues showing different growth 
patterns was studied using both the multistage and multigate/multistage model. Significant 
difference in tumour spectra in p53+/‘ and p53'/_ mice were found (eg different proportion 
of lymphomas or sarcomas). This finding is in accord with Donehower's hypothesis on the
XV
existence of 'windows of opportunity' for tumour development dependent on stem cell 
kinetics and stages required for tumorigenesis.
In future, the multigate/multistage model will be extended to simulate the effects of 
irradiation. It is hoped that some of the methods developed here will be applicable to 
tumour development in other mouse models, and ultimately to human cancer.
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Chapter 1
The Biology of Cancer
1
1.1 Introduction
Despite considerable progress, cancer is still a major cause of human mortality. In 
developed countries, cancer is the second most common cause of death (after 
cardiovascular diseases) and its importance is rapidly growing in developing countries. 
Although there many different types of cancer (more than 100), they share a common 
fundamental basis: abnormal growth and division of cells, which eventually spread through 
the body, invading and interfering with the function of normal tissues and organs. Cancer 
is thus fundamentally a disease at the cellular level, in which the cancer cell fails to 
respond to the controls that regulate normal cell growth and division. Such loss of growth 
control usually requires the accumulation of damage to several different cellular regulatory 
mechanisms.
The interaction of positive and negative signals to maintain cellular homeostasis is 
compatible with the basic yin-yang principle for the universe. In cancer, where homeostasis 
is impaired, mutations in genes responsible for sending or receiving the positive or 
negative signals accumulate and eventually lead to the disruption of homeostasis in growth 
regulation. An unknown number of mutations or pathways are needed for accomplishing 
this disruption; the number can vary depending on cell of origin and cancer type.
Moreover, cancers usually arise from the transformation of a single precursor cell, which 
proliferates to form a clone, i.e., tumours are most often monoclonal in origin. Despite 
their common origin, the cell populations in most tumours are quite heterogeneous with 
respect to their properties, suggesting that cancer cells continually modify their properties 
during the growth of the tumour.
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1.2 Multistep nature of tumorigenesis
A body of evidence exists to show that tumorigenesis is a multistage process (Table 1.1), 
which involves sequences of discrete genetic or epigenetic events probably differing from 
one tumour type to another (Barrett, 1987B and 1993; Farber, 1984; Fearon and 
Vogelstein, 1990; Vogelstein and Kinzler, 1993; Weinberg, 1989). Elucidation of these 
processes in terms of number and order of stages, and ultimately the identification of 
obligatory events in molecular terms, is a major goal of basic cancer research.
Table 1.1 Evidence for multistage models of carcinogenesis
• Mathematical models based on age-specific tumour incidence curves are 
consistent with a multistage model of neoplastic development involving 1 to 10 
independent alterations (see section 1.2.1)
• Chemical carcinogenesis studies in mouse skin and other tissues reveal that 
carcinogenesis involves stages of initiation, promotion, and progression (see 
section 1.2.2)
• Cell culture studies with chemical carcinogen-induced neoplastic transformation 
indicate that multiple changes must occur in the transformation of a normal cell to 
a tumour cell (see section 1.2.3)
• Inherited cancer (such as familial retinoblastoma, Wilms' tumour) requires a 
second, somatic mutation (see section 1.3.4)
• Tumorigenesis in transgenic and knock-out mice is consistent with a multistage 
process (see section 1.3.5)
1.2.1 Age—incidence relationship
Cancer can occur at all ages, but in most tumour types it becomes much more common 
with advancing age excluding the distinctive group of childhood tumours (Figure 1.1). The 
increasing incidence of cancer with age reflects a fundamental feature of the biology of
cancer cells. The conversion of a normal cell into a cancer cell does not occur as a single 
one-step event, because if a single mutation were responsible, occurring with a fixed 
probability per year, the chance of developing cancer in any given year should be 
independent of age. Rather, development of cancer involves a series of progressive changes 
that gradually convert a normal cell into a cancer cell. Usually, many years are required 
to accumulate the multiple abnormalities needed to generate most cancer cells, so the 
majority of cancers develop late in life.
For most types of cancer the incidence goes up very steeply with age, typically as the 
third, fourth, or fifth power. From such statistics it has been estimated that somewhere 
between three and seven independent events, each of low probability, are typically required 
to change a normal cell into a cancer cell (Renan, 1993).
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Figure 1.1 The age-incidence relationship (Vogelstein and Kinzler, 1993).
1.2.2 Animal experiments: initiation, promotion and progression
Animal experiments (mouse or rat) involving different tumour sites, such as skin, liver, 
breast and bladder, have identified and characterized three stages of the tumorigenic 
process: initiation, promotion and progression.
The studies of experimental tumorigenesis in skin, first started in the 1940's (Rous and 
Kidd, 1941; Berenblum, 1941; Friedewald and Rous, 1944), have led to the paradigm of 
"two-stage carcinogenesis", initiation and promotion. The multistage nature of the 
tumorigenic process was investigated further by Boutwell (1964) who proposed the concept 
that tumour promotion involves two stages. In this model, there are at least three stages 
in the tumorigenic process, i.e., initiation and two promotional stages. Consistent with the 
multistage theory, multiple types of lesions were identified by Bums et al (1976) during 
the course of mouse skin initiation-promotion studies.
Apart from skin, other animal organs in which reproducible initiation-promotion systems 
have been developed are the rat liver (Peraino et al., 1971; Farber, 1987; Farber and 
Sarnia, 1987), and the urinary bladder (Fukushima et al, 1983). An extensive review of the 
initiation-promotion literature prior to the nineteen eighties has been given by Farber and 
Cameron (1980) and by Farber (1984).
It is important to recognize that the later stages of neoplastic development involve 
distinctively different stages of promotion and progression. As reported by Hennings et 
al (1983), papillomas might be further induced to form carcinomas by initiators but not by 
promoters. By using the induction of hepatocelluar carcinoma (rat liver cancer) as a model, 
Farber (1984, 1987) and Farber and Sarma (1987) have demonstrated that each of three
5
phases (initiation, promotion and progression) may involve many steps.
1.2.3 Transformation in vitro
Studies using cell culture models of carcinogenesis have clearly demonstrated the 
progressive, multistep nature of neoplastic transformation. Berward and Sachs (1963 and 
1965) were first to demonstrate the induction by chemical carcinogens of neoplastic 
transformation of mammalian cells in culture. Following exposure to 3-methylcholanthrene 
or benzo(a)pyrene (BaP), Syrian hamster embryo fibroblasts (SHE) were observed to 
escape 'cellular senescence', the process which limits the proliferation of normal cells in 
culture to a certain number of cell divisions. The carcinogen-treated cells had an indefinite 
life span in culture, which has since been termed immortalization (Newbold et al, 1982), 
and were morphologically transformed. The morphologically altered cell lines ultimately 
produced malignant fibrosarcomas when injected into syngeneic hamsters (Berward and 
Sachs, 1963), whereas untreated SHE cells were nontumorigenic. Tumours can be produced 
by injections of less than 10 transformed cells while 107 to 109 normal SHE cells are 
nontumorigenic even after several passages in culture (Huberman and Sachs, 1966; 
Benedict et al, 1975; Barrett et al, 1979).
Morphological transformation is the earliest phenotypic marker that can be detected in SHE 
cells following carcinogen treatment (Barrett and Ts'O, 1978). Other phenotypic changes 
occur following carcinogen exposure with a different temporal sequence. Cells with an 
enhanced fibrinolytic activity are observed at 2 or 3 weeks, whereas cells with the ability 
to grow when suspended in a semisolid medium (i.e., soft agar) or able to form tumours 
when injected into syngeneic animals are not observed until 6 to 15 weeks after carcinogen 
treatment (Barrett and Ts'O, 1978). In this cellular system the ability to grow in agar
correlates very well with tumorigenicity for chemical carcinogen-induced transformation 
(Barrett et al, 1979). The inability to detect cells which grow in agar or as tumors in 
animals is not due to insensitivity of the assays to detect cells with these phenotypes. 
Rather, cells expressing the early phenotypic changes are preneoplastic and require 
additional changes to become tumorigenic. This hypothesis is supported by observations 
of a number of laboratories working with this system (Berward and Sachs, 1963, 1965; 
Borek and Sachs, 1966; DiPaolo and Donovan, 1967). Kuroki and Sato (1968) extensively 
studied the neoplastic transformation in vitro of SHE cells by 4-nitroquinoline-l-oxide (4- 
NQO). The earliest time at which cells capable of producing progressively growing 
tumours were obtained was 49 days after initial carcinogen treatment. In contrast, early 
changes in morphology were seen 3 to 4 days after treatment, and histological evidence 
of transformation was observed as early as 23 days after treatment. Furthermore, Kuroki 
and Sato identified three different stages in the neoplastic development of the transformed 
cultures, which they cite as evidence for progression in vitro. A diagram of the most 
common pathway for neoplastic transformation is shown in Figure 1.2.
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Figure 1.2 Neoplastic progression of Syrian hamster embryo cells (Barrett and Fletcher, 
1987)
Similar stages of neoplastic progression of other cell types in culture has also been 
described. For example, a number of stages in the transformation of guinea pig cells has 
been identified (Evans and DiPaolo, 1975 and 1982).
1.3 Genes and cancer
Neoplasms arise and progress through the accumulation of various genetic changes 
(Barrett, 1987A; Bishop, 1987, 1991 and 1995; Hall, 1993). These changes involve 
alterations of specific "cancer genes", generally divided into two major categories. One 
category is that of proto-oncogenes which, when activated by mutation, translocation or 
amplification, drives the process. The second broad category includes tumour suppressor 
genes whose function is lost (usually by inactivation) during tumorigenesis (Bishop, 1991). 
Thus, the continued acquisition of clonal alterations in proto-oncogenes and tumour 
suppressor genes drives the development of cancers.
1.3.1 Genetic alterations in tumour development
Cancer can be considered a genetic disorder of somatic cells (Cohen and Ellmein, 1991; 
Harris, 1986; Knudson, 1973, 1986 and 1995; Weinberg, 1988). Strong evidence from 
several areas of investigation validate this statement:
(1) chromosomal analysis reveals that cancer cells usually have abnormal karyotypes;
(2) some inherited syndromes are associated with an increased risk of cancer and for 
others, cancer itself occurs as an inherited trait (see section 1.3.4);
(3) cells can become malignant as a result of exposure to a variety of agents that damage
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DNA;
(4) some types of viruses can induce tumours (Bishop, 1987; Stoler, 1991; Varmus, 1984 
and 1988).
Each of the steps in tumorigenesis is thought to be the result of a genetic alteration, i.e., 
mutation, leading to increased cell growth. In this context, mutations are broadly defined 
to include any change in the genome (Table 1.2).
Table 1.2 Types of genetic alterations in tumorigenesis
• Gene mutations (base substitution, frameshift mutations, deletions and insertions)
• Gene duplication or amplification (increased number of copies of a gene) 
Chromosome aberrations (translocations, inversions, and deletions)
• Aneuploidy (abnormal numbers of chromosomes)
1.3.2 Proto-oncogenes
Proto-oncogenes are normal cellular genes that are responsible for positive growth signals 
(Cooper, 1990; Druker et al, 1989; Hesketh, 1994 and 1995). Activation of proto- 
oncogenes as oncogenes causes dysregulation of growth and differentiation pathways and 
enhances the probability of neoplastic transformation (Buckley, 1988; Cooper, 1990; Miller 
and Dmitrovsky, 1991).
The critical feature of proto-oncogenes is that they act in a dominant fashion, which means
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that the presence of a single copy of the gene in the cell is sufficient to produce the 
transformed phenotype, even in the presence of normal copies of the same proto-oncogene 
(see Table 1.3; Cooper, 1982).
Table 1.3 Properties of proto-oncogenes and tumour suppressor genes
Property Proto-oncogenes tumour suppressor gene
1. Number of mutational 
events required to 
contribute to the cancer
one two
2. Function of the mutant 
allele
gain of function, acts in a 
dominant fashion
loss of function, acts in a 
recessive fashion
3. Mutant allele may be 
inherited through the 
germ line
no examples at this time frequently has an inherited 
form
4. Somatic mutation 
contributes to cancer
yes yes
5. Tissue specificity of 
mutational event
some, but can act in many 
tissues
the inherited form 
commonly has a tissue 
preference
To date about 70-80 oncogenes have been identified (Hesketh, 1994 and 1995), but very 
few are known to be important to human tumorigenesis (Table 1.4). Members of the ras 
family are found most frequently: H-ras, K-ras, and N-ras. Activated ras oncogenes have 
been identified in most forms of human cancer (Bos, 1988 and 1989; Kiaris and Spandidos, 
1995).
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There are three principal mechanisms by which proto-oncogenes can be activated to 
produce a malignant cell: point mutation, chromosomal rearrangement or translocation, and 
gene amplification (Table 1.4; Cooper, 1990; Hesketh, 1994 and 1995). For example, a 
point mutation in N-ras is found in the cancer cells of most patients suffering from acute 
leukaemia (Bos, 1988). A translocation between chromosomes 2 and 8 is responsible for 
myc activation in Burkitt's lymphoma (Dalla-Favera et al, 1983). Gene amplification of N- 
myc is characteristic of many neuroblastoma (Brodeur et al, 1984).
Table 1.4 Oncogenes and human cancer
Oncogene Type of cancer Activation Mechanism
abl Chronic myelogenous leukaemia, acute lymphocytic 
lecukaemia
Translocation
bcl-2 Follicular B-cell lymphoma Translocation
E2A Acute lymphocytic lecukaemia Translocation
erbB-2 Breast and ovarian carcinoma Amplification
gip Adrenal cortical and ovarian carcinomas Point mutation
gsp Pituitary tumours Point mutation
c-myc Burkitt's and other B-cell lymphoma Translocation
Breast and lung carcinomas Amplification
L-myc Lung carcinoma Amplification
N-myc Neuroblastoma, lung carcinoma, rhabdomyosarcomas Amplification
RAR Acute promyelocytic leukaemia Translocation
H-ras Thyroid carcinoma Point mutation
K-ras Colon, lung, pancreatic, and thyroid carcinoma Point mutation
N-ras Acute myelocytic and lymphocytic leukaemia, thyroid 
carcinoma
Point mutation
ret Thyroid carcinoma DNA rearrangement
trk Thyroid carcinoma DNA rearrangement
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1.3.3 Tumour suppressor genes
In contrast to proto-oncogenes, tumour suppressor genes are normal cellular genes that are 
responsible for negative growth signals (Hesketh, 1994 and 1995; Hinds and Weinberg, 
1994; Levine, 1990 and 1993; Sager, 1989; Weinberg, 1991). Inactivation of tumour 
suppressor genes causes dysregulation of growth and differentiation pathways and enhances 
the probability of neoplastic transformation.
Unlike proto-oncogenes which act in a dominant fashion, tumour suppressor genes are 
recessive genes so that only homozygotes for the gene give rise to the cancer phenotype 
(see Table 1.3). In experimental systems, the introduction of functional tumour suppressor 
genes from normal cells into cancer cells results in loss of tumorigenicity (Harris, 1971; 
Stanbridge, 1976).
Rb gene was the first tumour suppressor gene to be isolated and studied at the molecular 
level, but the identification and characterization of additional tumour suppressor genes has 
rapidly followed these initial studies. To date, more than twenty distinct tumour suppressor 
genes have been isolated by molecular cloning (Table 1.5; Hesketh, 1995).
The type of mutations in tumour suppressor genes are most frequently point mutation 
(nonsense and missense mutation), deletions, insertions that produce either an absent or 
truncated protein product, and loss of whole chromosome segments or in some cases 
epigenetic changes in gene expression (Table 1.5; Harris, 1996; Reik, 1989; Scrable et al, 
1990; Stanbridge, 1990; Weinberg, 1991). The steps appear to be as follows: one 
chromosome of a pair is lost, and a deletion then occurs in the remaining chromosome, i.e. 
loss of heterozygosity (LOH).
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Table 1.5 Examples of tumour suppressor genes involved in human cancer
Gene Major types of 
mutation
Syndrome Typical neoplasms
APC Deletion and 
nonsense
Familial adenomatous 
polyposis
Carcinomas of colon, thyroid 
and stomach
ATM Deletion Ataxia telangiectasia Leukaemia, lymphoma
NF1 Deletion Neurofibromatosis 
type 1
Neural tumours
NF2 Deletion and 
nonsense
Neurofibromatosis 
type 2
Central schwannomas and 
meningiomas
p53 Missense Li-Fraumeni Carcinomas of breast and 
adrenal cortex; sarcomas; 
leukaemia; brain tumours
p lb1**4 Deletion and 
nonsense
Familial melanoma Melanoma
RBI Deletion and 
nonsense
Retinoblastoma Retinoblastoma;
osteosarcoma
WT1 Missense Wilms' tumour Wilms' tumour
VHL Deletion von Hippel-Lindau Hemangioblastoma and renal 
cell carcinoma
1.3.4 Hereditary cancer
Although the development of cancer is primarily sporadic in nature, non-random 
aggregations of the disease have been recognized to occur since the middle of the last 
century (Broca, 1866). Virtually every type of cancer has anecdotally been reported to 
occur in a familial form, yet convincing statistical evidence for hereditary or familial 
predisposition exists in less than three percent of all cases (Knudson et al., 1973; Knudson, 
1989 and 1996; Ponder, 1990).
The most striking form of genetic susceptibility involves Mendelian dominant inheritance 
with high penetrance and appearance of cancer at earlier than usual age, as shown for
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colon cancer in persons with familial adenomatous polyposis. In this example, the 
heterozygous state of the germ-line mutation imparts a high risk for just one form of 
cancer, while in other examples, such as the Li-Fraumeni syndrome, it predisposes to 
several kinds of cancer (but not to every type). The most frequent cancer in Li-Fraumeni 
syndrome is carcinoma of the breast, although it does not afflict all female carriers. But 
no known mutations predispose to all forms of cancer. It has been estimated that there may 
be 50 or so different genes in which mutations can impart high susceptibility to 
heterozygous carriers.
The fact that penetrance is incomplete for cancer mutations in the germline indicates that 
heterozygosity is not a sufficient condition for the development of cancer: something else 
must occur (This fact also indicates that tumorigenesis is a multistage process). For 
hereditary retinoblastoma Knudson (1971) supposed that this may be a second mutation, 
occurring post-zygotically.
Under the Knudson 'two-hit' hypothesis, the only difference between hereditary and non- 
hereditary cases was the timing of the first event as prezygotic or postzygotic, respectively.
1.3.5 Tumorigenesis in transgenic and gene knockout mice
The study of molecular mechanisms of tumorigenesis has been greatly enhanced in recent 
years by the advent of transgenic mouse technology, and use of germline manipulation for 
the creation of targeted gene mutation. By these technologies, the particular genes thought 
to be important in the tumorigenic process can be mutated or deleted in the germ line 
(Fowlis and Balmain, 1993; Gonzalez, 1996; Viney, 1995). Mice inheriting disrupted genes 
will, if the disrupted genes have been correctly chosen, require fewer mutational events in
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any somatic cell for malignant transformation to occur.
When an oncogene such as myc is transferred to the mouse germ line under the control 
of a breast-cell specific promoter, the transgenic animals develop breast tumours (Adams 
and Cory, 1991). However, of thousands of epithelial mammary stem cells in the mouse, 
only one or two become neoplastic. This suggests that the presence of a single oncogene 
is not sufficient for tumorigenesis, even when the gene is expressed at constitutively high 
levels for long periods. However, doubly transgenic mice, made by breeding myc 
transgenics with ras transgenic mice, develop tumours much earlier and more frequently 
(Sinn et al, 1987).
When a tumour suppressor gene such as Rb is disrupted by gene targeting, the knock-out 
mice develop tumours much earlier and frequently (Lee et al, 1992). However, most 
homozygous tumour suppressor gene knock-outs are lethal in mice at the fetal stage 
(Knudson, 1993).
1.4 Radiation carcinogenesis
Ionizing radiation may be the exogenous agent inducing more cancers than any other, 
because everyone is exposed to radiation from naturally occuring radioactivity, cosmic 
rays, medical applications and other sources. It induces cancer by mutating dominant-acting 
proto-oncogenes such as ras and myc to active form (Cox, 1994; Weichselbaum et al, 
1989), or tumour suppressor gene such as p53 or Rb to inactive form (Cowell, 1990; Cox, 
1994; Weichselbaum et al, 1989). Also, it kill cells, and thereby induces compensatory cell
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proliferation, which in turn leads to more mutagenesis during DNA replication.
1.4.1 DNA damage, repair and cell mutation
There is strong circumstantial evidence to indicate that DNA is the principal target for the 
biological effects of radiation. Therefore, a consideration of the biological effects of 
radiation must begin logically with a description of the breaks in DNA caused by charged 
particle tracks and by the chemical species produced.
A wide spectrum of DNA lesions is produced by ionizing radiaiton. These include a 
variety of base alterations, single-strand breaks, double-strand breaks and multiply damaged 
sites (Goodhead, 1994; Hutchinson, 1985; Urlaub et al, 1986; Wallace, 1983; Ward, 1988). 
Repair, non-repair or misrepair of these types of damage leads to the genotypic change 
responsible for the biological effect, such as cell killing and transformation (Hall, 1994; 
Hutchinson, 1993; Thacker and Cox, 1975; Ward, 1995).
The effects of DNA damage are greatly reduced by repair. The most common type of 
repair is excision of damage from one strand, with the complementary strand serving as 
template for resynthesis of the damaged strand (Price, 1993). This mechanism cannot repair 
double-strand breaks. Repair of double-strand breaks requires homologous DNA as 
template to rejoin the correct strands and replace any missing sequences (Price, 1993). This 
is probably the major pathway for repair of radiation-induced double-strand breaks in yeast 
(Game, 1993) andis. coli (Krasin and Hutchinson, 1977; Kobayashi and Takahashi, 1988), 
but its contribution in mammalian cells is not known, although there is evidence in these 
cells for repair of double-strand breaks.
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The nonrepair or misrepair of damage in DNA can lead to mutations and/or chromosomal 
abnormalities (Hutchinson, 1993; Thacker, 1992; Ward, 1995). Mutations can take a variety 
of forms including base alterations, frame-shift mutations and deletions (Hutchinson, 1993; 
Renan, 1992). Radiation can increase the frequency of specific mutations as well as 
chromosomal abnormalities (Sankaranarayanan, 1993; Ward, 1995).
1.4.2 Radiation tumorigenesis in experimental animals
Radiation carcinogenesis in animals is well documented (Fry and Storer, 1987; Fry, 1991; 
Silini, 1986; UNSCEAR, 1986 and 1988). Literally hundreds of studies have been done 
on animal models for radiation carcinogenesis, and it would be unproductive to review 
these reports in detail. Upton (1986) has, however, provided a very concise summary, as 
follows:
1. Neoplasms of almost any type can be induced by irradiation of an animal of 
suitable susceptibility, given appropriate conditions of exposure.
2. Not every type of neoplasm is increased in frequency by irradiation of animals 
of any species or strain.
3. The carcinogenic effects of irradiation are interconnected through a variety of 
mechanisms (see Section 1.4.3), depending on the type of tumour and conditions 
of exposure.
4. Some mechanisms of carcinogenesis involve direct effects on the tumour 
forming cells themselves, but others may involve indirect effects on distant cells 
or organs.
5. Though the dose-incidence curve has not been defined precisely for any 
neoplasm over a wide range of doses, dose rates, and radiation qualities, the 
incidence generally rises more steeply as a function of dose and is less 
dependent on dose rates with radiations of high LET than with radiations of low 
LET.
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6. The development of neoplasia appears to be a multicausal and multistage 
process, in which the effects of radiation may be modified by other physical or 
chemical agents.
7. At low to intermediate dose levels, the carcinogenic effects of radiation often 
remain unexpressed unless promoted by other agents.
8. At high dose levels the expression of carcinogenic effect often tends to be 
suppressed by sterilization of the potentially tranformed cells or by other forms 
of radiation injury, resulting in saturation or a turning point of the dose- 
incidence curve.
9. The distribution in time of radiation induced tumours characteristically varies 
with the type of tumour, the genetic background and age of the exposed animal, 
the conditions of irradiation and other variables.
10. Because of the diversity of ways in which irradiation can influence the 
probability of neoplasia, the dose-incidence relationship may vary accordingly.
It is very important to note that tumour incidence does not necessarily continue to increase 
indefinitely with increasing total-body dose.
1.4.3 Mechanisms of radiation carcinogenesis
Given the multistage nature of carcinogenesis (see Section 1.2), the molecular mechanisms 
involved in radiation oncogenesis are expected to be highly complex with radiation acting 
as one of a series of interacting factors. It is however possible to subdivide the whole 
process in the following simplistic fashion (Cox, 1994):
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(1) initial molecular damage to cellular DNA;
(2) post-radiation modification of that damage;
(3) the generation of specific gene or chromosomal mutations in appropriate target somatic
cells that initiate the oncogenic process;
(4) the early clonal expansion of initiated cells generating preneoplastic lesions;
(5) the accumulation of additional genetic and epigenetic events;
(6) further clonal evolution-selection that drives the progression and metastasis of the final
malignancy.
However it is quite possible that a need for further changes varies among tissues. 
Presumably these differences are due to differences in the importance of host factors and 
of the probability of the required change taking place spontaneously (Fry and Storer, 1987). 
It is also clear, and of considerable importance for risk estimation, that radiation of some 
tissues may convert normal cells into potential cancer cells that may never express their 
malignant phenotype or may do so only after a long time.
A frequent consequence of exposure to radiation is the loss of genetic material. Thus, 
activation of oncogenes and inactivation of tumour supressor genes by radiation may be 
part of a general mechanism of radiation-induced carcinogenesis (Cox, 1994). Guerreo et 
al (1984) found that mouse lymphomas induced by gamma radiation contained an active 
c-K-ras oncogene. After extensive molecular analysis, these investigators concluded that 
their results were compatible with gamma radiation as a source of point mutations which 
activated the c-K-ras gene in mouse lymphomas. The activation of the c-K-ras also appears 
important in the development of 90Sr induced osteosarcoma in mice (Merregaert et al, 
1986). Recently, Vahakangus et al (1992) found p53 mutations in lung cancer due to radon 
exposure.
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1.5 The role of p53 tumour suppressor gene in tumorigenesis
p53, the best known of the tumour suppressor genes so far, is thought to play an important 
role in the regulation of cell proliferation (Harris, 1996; Michalovitz et al, 1990; 
Selivanova and Wiman, 1995), and it has been suggested that the loss of normal p53 
function is associated with cell immortalisation or transformation in vitro (Dittmer et al, 
1993; Eliyahu et al, 1985; Hsiao et al, 1994; Jenkins et al, 1984; Pohl et al, 1988; Rovinski 
et al, 1988) and development of neoplasms in vivo (Ahuja et al, 1989; Baker et al, 1989; 
Takahashi et al, 1989; Vogelstein et al, 1988; Yokota et al, 1987). The alterations within 
coding sequences of the p53 tumour suppressor gene are among the most frequent genetic 
changes detected in human cancers (Beroud et al, 1996; Caron de Fromental and Soussi, 
1992; Harris, 1996; Hollstein et al, 1991 and 1996; Vogelstein, 1990). Reintroduction of 
p53 into transformed cells can induce either growth arrest (El-Deiry et al, 1993; Harper et 
al, 1993; Xiong et al, 1993) or apoptosis (Yonish-Rouach et al, 1991). The p53 gene or 
gene product is a common cellular target in tumorigenesis provoked by physical factors 
(Brash et al, 1991; Kemp et al, 1994), chemical carcinogens (Harvey et al, 1993; Kemp 
et al, 1993) or tumour viruses (Mowat et al, 1985; Wolf et al, 1987) (Figure 1.3).
1.5.1 The p53 tumour suppressor gene and its protein
The p53 gene encompasses about 16-20 kb of DNA located on the short arm of human 
chromosome 17 at position 17pl3.1 (Isobe et al, 1986; Miller et al, 1986). In the mouse, 
the p53 gene is found on chromosome 11 (Czosnek et al, 1984; Rotter et al, 1984). Both 
human and mouse genes are composed of 11 exons (Table 1.6). The first exon is 
noncoding, contains 213 base pairs and is found 8-10 kb away from exons 2-11. Thus, the
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first intron comprises about one-half of the gene. The p53 gene has been conserved during 
evolution. In cross-species comparison, the p53 proteins show five highly (>90%) 
conserved regions among the amino acid residues 13-19, 117-142, 171-181, 234-258, and 
270-286 ( Soussi et al, 1990).
Physical factors
■ radiation
■ UV-light
■ X-ray
p53 mutation 
or allelic loss
  Chemical carcinogens
■ polycyclic aromatic hydrocarbons
■ nitrosamines
■ afiatoxin
■ smoking
■ alcohol
p53 mutation 
or allelic loss
p53 gene and p53 protein
Germline mutations
Li-Fraumeni syndrome 
multiple malignancies 
diverse cancer-prone families 
increased susceptibility to tumour 
formation in transgenic mice
Tumour viruses
■ SV40 large T
■ adenovirus E IB
■ HPV E6
Specific cellular gene products
■ MDM2
Figure 1.3 Schematic representation of p53 as a common cellular target in tumorigenesis 
(Chang et al, 1993).
The product of the p53 gene from which it gets its name is a 393 amino-acid nuclear 
phosphoprotein (approximately 53 kD in molecular weight) and was identified when co-
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precipiteated in an antigen-antibody complex with extracts from the simian virus 40 (SV40) 
tumour antigen in 1979 (Lane and Crawford, 1979; Linzer and Levine, 1979). The p53 
protein was found in very low quantities in normal cells, but larger quantities of p53 (5- 
100 fold) could be detected in transformed cells in culture and in human tumours 
(Gusterson et al, 1991; Purdie et al, 1991).
Table 1.6 Properties of p53 tumour suppressor gene
p53
Nucleotides (kb) 16-20
Chromosome
Human 17p13.1
Mouse 11
Exons
Human 11
Mouse 11
mRNA(kb)
Human 2.5
Mouse 2.0
mRNA half-life (h) >12
Amino acids
Human 393
Mouse 390
Mass (kDa)
Human pp53
Mouse pp53
(expressed)
protein half-life 5-20 minutes (normal cells)
4-20 hours (transformed cells)
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1.5.2 The function of the p53 gene
Much of the early work on p53 was difficult to interpret as it was performed with mutant 
alleles which have carcinogenic properties (Eliyahu et al, 1984; Jenkins et al, 1984; Parada 
et al, 1984; Rovinski and Benchimol, 1988), and it is now clear that this gene in its non­
mutated form (wild-type) is a tumour suppressor gene which prevents carcinogenic change 
(Lane and Benchimol, 1990; Levine, 1992; Levine et al, 1991; Oren, 1992). Indeed the 
wild-type p53 is capable of reverting the transformed phenotype of many human tumour 
cell lines in vitro, i.e., causing human tumour cells in culture to revert to normal 
appearances and behaviour (Baker et al, 1990; Diller et al, 1990; Eliyahu et al, 1989; 
Finlay et al, 1989; Mercer et al, 1990; Harris, 1996).
The molecular mechanisms by which p53 functions normally, and by which it affects 
tumorigenesis remain unclear. As shown in figure 1.4, documented effects of wild-type p53 
on cell proliferation include regulation of the transition from G1 to S-phase of the cell 
cycle (Diller et al, 1990; Kastan et al, 1995; Livinstone et al, 1992; Perry and Levine, 
1993; Yin et al, 1992) and a role in determining cell death through apoptosis (Clarke et 
al, 1993; Donehower, 1994; Lowe et al, 1993; Midgley et al, 1995; Oren, 1994; White, 
1996; Yonish-Rouach et al, 1991). Biological analysis indicated that p53 plays little part 
in normal cell cycle control, but plays an important growth-controlling role in stressed cells 
(Kastan et al, 1992; Lane, 1992). Emerging evidence also suggests that p53 appears to 
function normally as a Gl-S checkpoint control for DNA damage (Hartwell, 1992; Kastan 
et al, 1992; Lane, 1992; Lee et al, 1994 Selivanova and Wiman, 1995). Accordingly, 
normal p53 may act as a 'molecular policeman1 monitoring the integrity of the genome. If 
DNA is damaged, p53 accumulates and switches off replication to allow extra time for 
repair mechanisms to act. If this fails however, p53 may trigger cell suicide by apoptosis
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(Lane, 1992).
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Figure 1.4 The hypothesized role of p53 in normal cells and the effects of its absence on 
development of a tumour cell.
These regulatory functions may be mediated by the interaction of p53 protein with specific 
DNA sequences (Hupp et al, 1992; Kern et al, 1991; Kern et al, 1992; Ko and Prize, 1996) 
which may allow regulation of other genes at transcriptional level (Donehower and 
Bradley, 1993; Farmer et al, 1992; Ko and Prizer, 1996), or perhaps by initiating DNA 
replication (Friedman et al, 1990; Ko and Prizer, 1996). It has been presumed that wild- 
type p53 could regulate the assembly or function of DNA replication-initiation complexes, 
or alternatively, p53 could act as a transactivator of gene transcription, either promoting 
or inhibiting mRNA synthesis(Levine et al, 1991; Ko and Prizer, 1996). In mutated p53 
proteins, the DNA binding capacity, transcriptional activator function and initiation of
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DNA replication are all altered (Friedman et al, 1990; Farmer et al, 1992; Hupp et al, 
1992; Kern et al, 1992; Lane and Benchimol, 1990; Park et al, 1994; Pietenpol et al, 1994; 
Zhang et al, 1994).
1.5.3 p53 and genomic stability
p53 has been proposed to be involved in maintaining stability of the genome (Livingstone 
et al, 1992; Smith and Forance, 1995; Yin et al, 1992), and both cell cycle arrest and 
apoptosis can be considered mechanisms by which this may be accomplished. In the 
presence of DNA damage, cells will either arrest, presumably to allow DNA repair, or 
undergo cell death, in a p53-dependent manner. In either case, the propagation of 
potentially deleterious mutations can thus be averted.
Consistent with a role for p53 in protecting genomic integrity, fibroblasts from p53- 
deficient mice demonstrate chromosomal abnormalities that appear at early passage in 
homozygous null fibroblasts and at later passage in heterozygous fibroblasts (Harvey et al, 
1993C). Aneuploidy and evidence of chromosomal instability was also found in tumours 
from p53 homozygous null mice and from mice with both a Wnt-1 transgene and 
homozygous for the null allele of p53. Finally, fibroblasts from p53 homozygous null mice 
become tetraploid and octaploid after exposure to spindle inhibitors, in contrast to those 
from wild-type mice, which undergo arrest (Cross et al, 1995).
p53-deficient cells exhibit a higher tolerance to genetic abnormalities arising from radiation 
as well as spontaneously. In response to y-irradiation, cell from mice homzygous for the 
null allele show increased accumulation of double-stranded DNA damage as compared to 
heterozygotes or wild-type littermates (Bouffler et al, 1995; Lee et al, 1994).
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1.5.4 Association of p53 with tumorigenesis
Is alteration of function of the p53 pathway a prerequisite for neoplastic transformation? 
The frequency of p53 mutations in human and animal tumours argues for a critical role 
(Beroud et al, 1996; Donehower et al, 1992; Hollstein et al, 1996; Purdie et al 1994). Of 
the about 6.5 million cancer cases worldwide each year, 2.4 million tumours are estimated 
to contain a p53 mutation (Harris, 1996). But for most tumour types mutations have been 
found only in 20-50% of cases (Table 1.7). Current techniques are unlikely to miss more 
than 15-20% of coding sequence abnormalities. How frequent and important to functional 
abrogation are mutations in the p53 promoter or unevaluated introns, epigenetic 
inactivation of p53, and/or alteration of gene or proteins downstream in the p53 pathway?
Is p53 only one of several pathways whose disruption is sufficient for neoplastic 
transformation? Support for this concept comes from the observation that both p53 and ras 
mutations are common events but often occur independently (Enomoto et al, 1993; 
Kalthoff et al, 1993; Lehman et al, 1991; Mitsudomi et al, 1992; Nikolaidou et al, 1993; 
Shaw et al, 1991), and either may be associated with aggressive tumour behaviour (Dowell 
and Hall, 1994; Harris and Hollstein, 1993; Rodenhuis and Slebos, 1992).
Does neoplastic transformation require a "critical mass" of genetic injury, in which p53 
abberration is a frequent but not causally essential event? In this scenario, loss of p53 
genomic stabilization properties would predispose a cell to an acceleration in the rate of 
genetic damage and greatly increase the likelihood of neoplastic transformation and/or 
malignant progression. Research which attempts to unify molecular and cellular theories 
of carcinogenesis should address these and other questions. Evaluation of mutation patterns 
of p53 and other genes in clinical tumours can be an important part of this process.
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Table 1.7 Incidence of p53 mutations in human cancer
Cancer % of samples in which p53 
mutations occur
References
Acute myeloblastic leukaemia 6 Hu et al, 1992
Brain tumours -10 Mashiyama et al., 1991
Breast cancer 53-86 Horak et al., 1991; 
Varley et al., 1991
Colorectal cancer 50 Rodrigues et al., 1990
Epithelial skin (basal cell) 
carcinoma
48 Moles et al., 1993
Oesophageal cancers 50 Bennett et al., 1991
Gastric carcinoma 57 Martin et al., 1992
HBV-positive hepatoma 
Lung tumours
18 Hosono et al., 1993
Small-cell carcinoma 44-73 Iggo et al., 1990; 
Takahashi et al., 1991
Non-small-cell carcinoma 45 Takahashi et al., 1991
Adenocarcinoma 57 Iggo et al., 1990
Squamous cell carcinomas 34-82 Gusterson et al., 1991; 
Iggo et al., 1990
Carcinoid 0 Iggo et al., 1990
Malignant astrocytomas -30 Mashiyama et al., 1991
Melanomas (primary) 97 Akslen and Morkve, 1992
Multiple myeloma 20 Portier et al., 1992
Osteosarcomas 41 Mulligan et al., 1990
Ovarian carcinomas 44 Milner et al., 1993
Pancreatic carcinomas 40 Ruggeri et al., 1992
Rhabdomyosarcomas 45 Mulligan et al., 1990
Squamous cell carcinoma of the 
larynx
60 Maestro et al., 1992
Thyroid carcinomas 50 Dongi et al., 1992
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Germinal mutations in the p53 gene have been observed in some families with the Li- 
Fraumeni syndrome, an autosomal dominant disease characterized by a greatly increased 
predisposition to cancer of various types (Malkin, 1994; Malkin et al., 1990; Srivastava et 
al., 1990). Roughly 50% of family members with Li-Fraumeni syndrome develop 
neoplasms by the age of 30, in contrast to an incidence of 1% cancer development by age 
30 in the general population (Malkin et al., 1990). Furthermore, all the tumour-affected 
individuals retain the mutant allele and lose the wild-type p53 allele in their tumour tissue.
1.5.5 Tumorigenesis in p53 deficient mice
The animal model which has provided greatest insights into the activities of p53 in 
tumorigenesis is the p53-deficient mouse developed by gene targeting techniques 
(Donehower et al, 1992). It was demonstrated that mice homozygous for a null p53 allele 
were developmentally normal but highly susceptible to early onset of tumour. By the age 
of 6 months, 74% of the homozygotes had developed tumours and by ten months all of 
these mice had died or developed tumours. The spectrum of tumours observed were fairly 
diverse, although lymphomas predominated. However, the heterozygote mice also displayed 
an elevated level of tumour susceptibility, although the tumours in this group developed 
at a later age in a lower fraction of the mice. By 15 months of age, 27% of the 
heterozygotes had developed tumours of various types. However, instead of lymphomas, 
osteosarcomas and soft tissue sarcomas were the predominant tumour type in the 
heterozygotes. Clearly, these p53 deficient mice provide definitive proof that p53 behaves 
as a tumour suppressor gene. In addition, the heterozygous mice may serve as a useful 
model for the Li-Fraumeni syndrome.
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Recently, preliminary studies on radiation-induced tumorigenesis showed that 4 Gy single 
treatment of gamma rays resulted in a marked reduction in median tumour latency in p53 
heterozygous mice (Kemp et al, 1994), a lesser reduction in p53 null mice and negligible 
effect in the wild-type mice. Moreover, tumours developing in irradiated p53 heterozygous 
mice, when subjected to Southern blot analysis, were consistently found to be p53 null. 
These results imply that p53 inactivation may be a near-obligatory step in radiation 
tumorigenesis in these mice and pose critical questions as to the sensitivity of the p53 
allele to radiation inactivation and the frequency of occurrence of full malignant 
transformation of a cell in which both p53 alleles have been inactivated. The present 
findings are consistent with high radiosensitivity of the p53 gene and a high probability 
of occurrence of further transforming events once p53 inactivation has taken place (i.e. an 
operational genomic instability). This could have important implications for Li-Fraumeni 
patients if the murine findings are more generally applicable.
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Chapter 2
Multistage Models for Tumorigenesis
30
2.1 Introduction
In contrast to the extreme diversity and complexity of the biological observations and 
theories on tumour development described in Chapter 1, the quantitative description of 
tumorigenesis is still rudimentary. The conceptualiztion of tumorigenesis as a probabilistic 
multistage process led, in the 1950s, to the definition of the multistage model (Nording, 
1953; Armitage and Doll, 1954 and 1957). The only assumption made by the multistage 
model is that, to become fully malignant, cells have to undergo a series of rate-limiting 
transformation events whose time of occurrence is exponentially distributed (see Section 
2.1). Within such a framework, carcinogens are supposed to act by increasing the 
probability of transformation from one stage to another. With some methodological 
refinements (Crump and Howe, 1984; Crump et al, 1977; Krewski et al., 1983; Little et 
al, 1992; Murdoch and Krewski, 1988; Whittemore and Keller, 1978) this model is still 
the most widely used.
The discovery and confirmation that the loss of two copies of the retinoblastoma (Rb) gene 
could lead to a fully malignant tumour (Benedict et al, 1983; Hethcote and Knudson, 1978; 
Knudson, 1971; Knudson et al, 1975), and that the clonal expansion of pre-malignant cells 
was important (Nowell, 1976), led to the development of a series of closedly related clonal 
two-stage models for which a considerable literature now exists (Greenfield et al., 1984; 
Knudson, 1971; Moolgavkar, 1990; Moolgavkar and Knudson, 1981; Moolgavkar and 
Venzon, 1979; Tan, 1991). Most clonal models developed so far assume that two 
mutational events are required to form a fully malignant cell. Initiators are supposed to act 
by increasing the probability of these events (Moolgavkar et al, 1990; Portier, 1987), while 
promoters are supposed to induce the proliferation of intermediate stage cells (Cohen and
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Ellwein, 1990; Moolgavkar, 1983), therefore increasing the size of the susceptible cell 
populations. In section 2.3, the Moolgavkar-Venzon-Knudson (MVK) model will be 
discussed in detail.
As demonstrated in Chapter 1, tumorigenesis is a multistage random process with 
intermediate cells subjected to stochastic cell proliferation and differentiation. These 
observations led to the extension of the MVK model into a multistage model (Little, 1995; 
Moolgavkar and Luebeck, 1992; Tan, 1991) that will be discussed in detail in Section 2.4.
Multistage models may be generalised to the situation of competing alternative pathways 
and to a still more general class of model, described by Portier et al. (1993) as 
multistage/multihit models in which traditional multistage pathways (requiring sequential 
occurrence of mutational events) coexist with multihit processes (for which a critical 
burden of events may be acquired in any order). These more general models are still quite 
new, their application to tumorigenesis will probably become more common as molecular 
genetic information on alternative pathways becomes available.
2.2 The Armitage-Doll multistage model
Multistage models for single cell carciongenesis were first advanced in the 1950s by 
Armitage and Doll (Armitage and Doll, 1954) to explain the observation that, in many 
adult carcinomas, the logarithm of the age-specific incidence rates increases linearly with 
the logarithm of age. Fisher and Hollomon (1951) suggested that this observation could be 
explained if a critical number of six or seven tumour cells were required for subsequent
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independent tumour growth. The Fisher-Hollomon hypothesis is not now believed to be 
correct and modem tumorigenesis models are descendants of the Armitage-Doll concept - 
the multistage transformation of a single cell.
Figure 2.1 illustrates the basic theory behind the Armitage-Doll model. The model views 
carcinogenesis as the end result of a sequence of many steps, i.e., any single cell may 
transform from the normal state through many intermediate states into a malignant state. 
Consider a series of k steps through which a normal clonogenic cell must pass sequentially 
in order to reach the end state of full-blown malignant transformation, and X^ (j=l,2,3, ..., 
k) represents the "rate of transition" from stage j-1 to stage j, where stage 0 is the normal 
state and stage k+1 is the malignant state.
-k-l Malignant
Cell
Normal
Cell
Stage Stage
k-l
Figure 2.1 The Armitage-Doll multistage model of carcinogenesis
An intuitive derivation of the age-specific incidence predicted by this model then proceeds 
as follows: let p;(t) be the probability that the ith event has occured by time t. Then
Pi(t+At)=p,(t)+A.,At[l-p,(t)] (2.2.1)
i.e. dpi(t)/dt = Xi[l-Pi(t)] (2.2.2)
so pi(t)=l-exp(-A,it) (2.2.3)
Thus the probability that all events have occured by time t is p](t)p2(t)—pk(t). It may be 
shown that P(t), the probability function of appearance of the tumour by time t or less, is
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given by:
k
where N the is the total number of susceptible cells in the tissue and t is a fixed positive 
time for the growth of the tumor.
If the mutation rates 7^  (j=l, 2, ..., k) are very small, the probability of the appearance of 
the tumour, P(t) , is approximately given by:
P( t )  ~ N  A Xl X2. . .Xk ( t -  z ) k (2.2.5)
where A is a compound constant ( a function of the X terms).
The approximate age-specific incidence rate, I(t), predicted by the Armitage-Doll model
is
m  - E E
dt
- N  A X,X0. . .Xk k  ( t - x ) k- ]
(2 .2 .6)
= B X1X2. . .Xk ( t ~ T ) k' x 
where B is a compound constant.
It is noteworthy that the first exposition of the Armitage-Doll model multistage theory 
appeared only a few years after early, seminal work on initiation-promotion in mouse skin. 
It took many years for experimentalists to demonstrate that initiation and promotion were 
not idiosyncratic responses of mouse skin, but components of carcinogenesis of general 
relevance (Farber et al, 1987). It was evident much earlier, on statistical and 
epidemiological grounds, that a multistage process provided a parsimonious and coherent
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explanation of many different phenomena.
In 1969, Cook, Doll and Fellingham undertook a comprehensive test of the relationship 
(2.2.4) for the age distribution of cancer. They tested this relationship in 31 types of cancer 
in 11 populations, and concluded that the constant k "might be a biological constant 
characteristic of the tissue in which cancer is produced." However, these authors also 
concluded that in a large number of data sets, the age-specific incidence rates showed 
significant departures from the simple relationship (2.2.4). Some possible reasons for these 
depatures were discussed by the authors. A fuller discussion is to be found in a thoughtful 
article by Peto (1977).
Epidemiologic data on exposure to specific carcinogens has been examined within the 
framework of the Armitage-Doll model by various authors (Brown and Chu, 1982; Day 
and Brown, 1980; Little, 1996; Little et al, 1992 and 1995; Thomas, 1982). By studying 
the pattern of evolution of risk after exposure to a carcinogen begins and after exposure 
stops, it is possible to deduce whether an early or a late stage (or both) is affected by the 
carcinogen.
That the Armitage-Doll model successfully describes the age-specific incidence curves of 
a large number of human tumors does not provide strong evidence in favor of its 
correctness. Many other models fit the age-specific incidence data equally well. The 
ultimate vindication of a model must derive from biological considerations. In this regard, 
the Armitage-Doll model is somewhat unsatisfactory. First, the Armitage-Doll model 
provides no satisfactory explanation for hereditary tumours such as retinoblastoma and 
Wilms' tumour. Second, initiation-promotion experiments and a host of other considerations 
suggest that both mutations and cell proliferation are important in carcinogenesis: the
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Armitage-Doll model makes no explicit allowance for cell growth and differentiation. Thus, 
the initiation-promotion and initiation-promotion-initiation experiments cannot be explained 
by the Armitage-Doll mulitstage model.
2.3 Moolgavkar, Venzon and Knudson two-stage model
Moolgavkar, Venzon and Knudson (Moolgavkar and Venzon, 1979; Moolgavkar and 
Knudson, 1981) have proposed a model (MVK model) for carcinogenesis that assumes that 
a tumour develops from a single normal stem cell by clonal expansion and views 
carcinogenesis as the end result of two discrete, heritable and irreversible events in normal 
stem cells. Each event occurs during a single cell division. It differs from the Armitage- 
Doll model in that the normal stem cells and intermediate cells are subjected to cell 
proliferation and cell differentiation and death (see Figure 2.2). A distinct feature of this 
model is that the first event may occur either in germline cells or in somatic cells but the 
second event always occurs in somatic cells.
2.3.1 Assumptions
According to this model, there are three types of cells: the normal stem cells, the 
intermediate (or initiated) cells and tumour cells. Further, with probability one, a tumour 
cell will develop into a malignant tumour. We denote the number of normal stem cells, 
intermediate cells and tumour cells by X(t), Y(t) and T(t) at time t, respectively. To find 
the age specific incidence function of tumours and the probability distribution of the time 
required for a normal stem cell to develop into a tumour, we make the following
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assumptions:
(1) Each susceptible stem cell in a tissue experiencess malignant transformation 
independently of the other susceptible stem cells.
(2) In the small time interval (t, t+ A t) ,  a normal susceptible cell divides into two 
normal susceptible cells with probability b]At+ c(At); it dies or differentiates with 
probability d]At+ o (A t); and it divides into one normal cell and one intermediate 
cell with probability | i 1A t+  c (A t);  the probability of more than one event occuring 
is c (A t) .
(3) Likewise at time t, an intermediate cell divides into two intermediate cells, dies 
(or differentiates), or divides into one intermediate and one malignant cell with 
parameters b2, d2, and p2, respectively.
Figure 2.2 MVK two-stage model of carcinogenesis. N, I and T stand for normal stem 
cells, intermediate cells and tumour cells, respectively. D stands for death/differentiation.
2.3.2 Incidence function
There are two fundamental quantities: the first is the incidence function, I(t), at time t; the
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second is the probability, P(t), that a malignant cell is generated by time t.
t
P ( i ) = l - e x p [ -  ( I(s)ds]  (2.3.1)
0
To obtain the incidence function and the probability of the occurrence of tumour, an 
important mathematical tool is the probability generating function (PGF) of the number of 
normal cells, intermediate cells and tumour cells, i.e., X(t), Y(t) and T(t). The PGF of X(t), 
Y(t) and T(t), T ^x^z; t), is defined by:
¥(>,.>>,z;r) = J 2 p r i X ( t )  = i , Y ( t ) =j , T ( t ) =k  } x* y j z k (2.3.2)
i j . k
Given the PGF T(x,y,z; t), one may not only compute the probability of having k tumours 
by time t, but also can derive the incidence function I(t) of tumours using the following 
relationship:
I ( t )  = - ' I ' /( l , 1 . 0 ; 0  / ¥ ( 1 ,1 , 0 ; * )  (2.3.3)
where 'Pt(l,l,0;t) = dT^LLOitydt.
To find out the PGF T ^x^z; t), an important mathematical equation is the Kolmogorov 
forward differential equation.
Let p(i, j, k; t) = Pr{ X(t)=i, Y(t)=j, T(t)=k }; then, the differential equations of p(i, j, k; 
t) are obtained by considering two contiguous time intervals (0, t) and (t, t+At). The 
probabilities p(i, j, k; t+At) are:
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p(i,j,k;t+*t) ={1 -[z(^j  +dl +iLl)*t+j (b2+d2 + \i2)*t]} p( i j , k ; t )
+ ( i - l ) b ]*t p ( i - l , j , k ; t )
+ (i + l )d l *t p( i  + l J , k \ t )
+ W  ~ 1 )*2 + i h  ] *  p ( i j  ~ 1 ,k;t)
+ (j + l ) d 2£j p ( i j  + l , k; t )
+j\i2*t p { i j , k ~  1 ;0  + o(a/)
Using (2.3.4), we obtain that, 
d—  p( i , j , k ; t )  = - [ / ( * ,  +d + \i ) +j(b +d +ii ) ] p ( i j , k ; t )  
dt
+ ( i - l ) b ]p ( i - \ , j , k ; t )
+ (i + \ ) d ]p( i  + l , j , k; l )
+ [ ( j ' l ) b 2 + i\il ]p( i J - l , k ; t )
+ (j + l ) d 2p( i , j  + l , k; t )
+j ^ 2P ( h j , k - l , t )
Equations (2.3.5) are called the Kolmogorov forward differential equations.
Hence, xF(x,y,z; t) satisfies the following equations:
>P/( 0  = 5 'P / dt
= xy + b^x2 +d} -  +d} + jijx }  d ^ / d x
+ i\x2y z  + b2y 2 + d2- [ b 2 + d2 + \i2]y) d Y / d y  
with the inital condition xE(0)=x where the dependence of ¥  and *P on x, y
(2.3.4)
(2.3.5)
(2.3.6)
, z has been
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suppressed for notational convenience. From (2.3.6) we have
dy (2.3.7)
and thus
7 (0  = h2£ [ 7 ( 0  17X0 = 0] (2.3.8)
It should be noted that (a) the transition rates m and p2 are multiplicative factors and are 
important in determining the overall incidence rates of cancer in question (however, they 
do not influence the shape of the incidence curve), and (b) the shape of the incidence curve 
is determined by the growth curve of the normal tissue and the cellular kinetics of 
intermediate cells (Moolgavkar, 1986A; Moolgavkar and Knudson, 1981).
The MVK model has been widely used to analyze various experimental and 
epidemiological data (Moolgavkar and Knudson, 1981; Moolgavkar and Luebeck, 1990; 
Tan, 1991), and to interpret some important biological phenomena which include initation- 
promotion phenomenon (Moolgavkar and Luebeck, 1990; Tan and Gastardo, 1985), 
hormone effects in human female breast cancer (Moolgavkar, 1986B), familial human 
cancers (Moolgavkar, 1986A; Moolgavkar and Knudson, 1981; Tan and Singh, 1990), 
premalignant lesions (Dewanji et al, 1989 and 1991; Luebeck and Moolgavkar, 1991; 
Moolgavkar and Knudson, 1981), and in vitro analysis of carcinogenesis (Nettesheim et 
al, 1987). It appears that the initiation-promotion phenomenon is well explained by the 
two-stage models with the specification that initiators affect the rate of the first event while 
promoters facilitate the increase of the proliferation rate of intermediate cells. The familial 
human cancers are explained by the two-stage models by the feature that the first event of
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the two-stage models may occur in germline cells.
The MVK model may also be used to assess risks of environmental agents and to classify 
carcinogens (Luebeck et al, 1996; Moolgavkar, 1990; Moolgavkar et al, 1988, 1990A, 
1990B and 1993; Van Ryzin, 1980; Tan, 1991).
2.4 Multievent model
As demonstrated in Chapter 1, cancers develop from individual normal cells which have 
undergone a series of changes affecting important genes. The number of mutations required 
depends on the tumour type and varies from 1 to 10 (Renan, 1993). This observation has 
led to the extension of the MVK two-stage model to a multistage model with cell 
proliferation and cell differentiation or death for normal stem cells and intermediate cells 
(Chu et al, 1987). This model is called as the multievent model to distinguish it from the 
classical Armitage-Doll multistage model.
A schematic representation of the multievent model is given in Figure 2.3. Like the 
Armitage-Doll multistage model, the transformation of a normal stem cell into a tumour 
cell requires a series of k sequential changes or stages. In addition, a cell in each stage 
may not only progress to the next more malignant-like stage, but may proliferate or 
differentiate/die.
The incidence rate of tumours at time t, I(t), can be derived by the same method for MVK 
model (for details see Tan (1991, chapter 6)).
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Figuer 2.3 A multievent model involving k stages for carcinogenesis.
Recently, Moolgavar et al (1993) applied a multievent model to the development of human 
colon cancer and concluded that a three-event model provided a better description. Little 
(1995), studying radiation-induced cancers also found a three-stage model appropriate for 
several tumour types. Since the multievent models were only recently proposed, the 
implications of this category of model have not yet been fully worked out.
2.5 Multipath/multistage model
With recent progress in molecular biology, current research in cancer has moved beyond 
solely collecting tumour incidence data. Reseachers are able to obtain more sophisticated 
data that describe the mechanisms of tumorigenesis through a variety of experimental 
designs. The data collected from these experiments may include multiple stained enzyme-
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altered premalignant and malignant focal lesions, labelling index, and other biomarkers. 
Schwarz et al. (1989) have observed heterogeneity between single phenotype lesions and 
multiple phenotype lesions (multiple stained lesions) in experiments where enzyme-altered 
foci were obtained from rat liver. A single-path process (multistage model) is not adequate 
to describe their observations, a multipath model is more appropriate. Observations in 
human colon tumorigenesis (Fearon and Vogelstein, 1990) also point to multiple pathways 
for the process of cancer. These observations have led Tan and Chen (1990), and Sherman 
and Portier (1994) to develop the multipath/multistage model.
A two-path/two-stage model is shown in Figure 2.4. There are two possible paths for a 
normal cell to be transformed into a malignant cell: (1) normal cell -»  initiated cell A —> 
malignant cell and (2) normal cell —» initiated cell B —> malignant cell. A tumour develops 
independently by either of the two two-stage pathways.
birth
birth
differentiation
or
death
birth
b 12
differentiation
or
death
Initiated 
Cell B
Normal
Cell
Initiated 
Cell A
Malignant
Cell
differentiation
or
death
Figure 2.4 A two pathway model involving two-stage models of cacinogenesis.
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For the model shown in Figure 2.4, it is also assumed that normal stem cell, intermediate 
cell A and intermediate cell B undergo growth via a linear birth-death process. As in the 
MVK model, it is also assumed that one malignant cell grows into a tumour with 
probability one. Let P^t) and P2(t) be the probability of a malignant cell being generated 
via the upper and lower paths by time t, respectively. The probability, P(t), of a malignant 
cell being generated via by any of the two pathways is given by:
P(t)=[l-Pi(t)][l-P2(t)]
Both two-path/two-stage and three-path/one-stage models have been used to describe the 
transformation of normal cells into single and multiple phenotype enzyme-altered cells in 
rat hepatocarcinogenesis by Sherman and Portier (1995). The three-path/one-stage model 
tends to fit the observed size distribution data for the multiple phenotype lesions better 
than the two-path/two-stage model. However, in both cases the fit of the models falls short 
of that for the single phenotype lesions.
2.6 Overview of present studies
Stochastic modelling of multistage tumorigenesis, reviewed as above, has been influential 
in consideration of general features such as number of stages but has not as yet provided 
insights at the molecular level.
Recent progress in molecular oncology, primarily the identification of candidate oncogenes 
and tumour suppressor genes in particular tumorigenic pathways has raised the possibility
i
!
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of detailed mapping of some such pathways in molecular terms. In such investigations, it 
will be important to have analytic tools for experimental data processing which facilitate 
the testing of specific hypotheses regarding the tumorigenic pathway. In the investigations 
described in this thesis, mathematical tumorigenesis models will be developed, which are 
intended to help in the elucidation of tumorigenic pathways involving alterations to the 
structure or function of the p53 gene.
Prelimary modelling work was begun to explore p53 mediated spontaneous and radiation- 
induced tumorigenesis in mice (Chapter 3, 4, 5 and 6). The initial studies focused on the 
development of stochastic process (birth-death) models (extension of MVK model) in 
which 3 stages are required for malignant transformation of a somatic stem cell in a target 
tissue. These stages are intended to represent the inactivation of one and both p53 alleles 
with a third, genetically unspecified stage which may be composite. Then, tumorigenesis 
in wild-type (p53+/+), p53 heterozygous (p53+/‘) and p53 homozygous null (p53';') mice 
would require 3, 2 and 1 stage respectively. The model is intended to apply to all stages 
of mouse development post-conception and includes a stochastic reformulation of a 
deterministic 'Gomp-Ex' growth model (Wheldon, 1988) for stem cell number. Realistic 
parameter values were chosen where possible but the intention is to seek robust 
conclusions not heavily dependent on particular values. In the whole studies, we 
established a set of computer simulations for implementing all proposed models, explored 
the properties of these model in order to better understand the consequences of the model 
assumptions.
In Chapter 3, the work is confined to spontaneous tumorigenesis and involved exploration 
of the effect of changing number of stages, ultimate (i.e. steady-state) stem cell number 
and mutation rate on the timing of appearance of tumours. In Chapter 4, the model will
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be extended to simulate the effect of single doses of irradiation. Irradiation was modelled 
as causing both transforming and lethal cellular mutations. The predicted dose-dependence 
of tumour latency for each genotype, for irradiation at different developmental stages, is 
examined, and the optimal time (age) of irradiation for maximum yield of tumours is 
predicted. In Chapter 5 and 6, attention is given to tumour multiplicity in non-irradiated 
and irradiated mice respectively in order to resolve a current paradox (P53''" mice are seen 
to develop only a few tumors per mouse though all somatic stem cells are at risk). Both 
studies showed the model extended from the MVK models was not compatible with 
experimental data in p53 deficient mice.
Thereafter, two categories of explanation for this paradox were proposed. The first of these 
(Chapter 7), the multistage multipath model invokes a p53 independent pathway which 
exists in parallel with a p53 mediated route of tumorigenesis. The other, discussed in 
Chapter 8, which we called the multigate/multistage model postulated a single pathway (or 
gateway) with several gate-pass events (obigatory mutations) occuring at a rate which 
depends on p53 status.
Finally, the competitive tumour development in tissues that follow different growth patterns 
was introduced into multistage and multigate/multistage models and were used to explore 
the effect of growth pattern on tumour spectra (i.e tumours of differing pathological type) 
(Chapter 9). Some preliminary experimental studies, intended to estimate the in vivo 
mutation rate as a function p53 genotype, are described in Chapter 10.
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Chapter 3
A Multistage Model for Tumorigenesis in Developing 
and Adult p53 Deficient Mice
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3.1 Introduction
The study of molecular mechanism of tumorigenesis has been greatly enhanced in recent 
years by the advent of genetically engineered (transgenic) mice in which particular genes, 
thought to be important in the tumorigenic process, are mutated or deleted in the germ line 
(Fowlis and Balmain, 1993). Mice inheriting disrupted genes will, if the genes have been 
correctly chosen, require fewer mutational events in any somatic cell for malignant 
transformation to occur.
In particular, several laboratories have now developed transgenic mouse strains in which 
one or both normal copies of the p53 tumour suppressor gene have been inactivated in 
each somatic cell of the mouse (Donehower et al., 1992). Inactivation or mutation of p53 
has been implicated in a wide range of tumour types in man (Caron de Fromental and 
Soussi, 1992; Hollstein et al., 1991) and in several animal species (Mowat et al., 1985; 
Levine et al., 1991). For tumours which develop via disruption of p53, and which usually 
require N mutations in total for malignant transformation, transgenic mice are available 
which have almost identical genotypes but require N, N-l and N-2 mutational events for 
malignant transformation. The existence of mouse strains which differ only in the number 
of stages required for malignant transformation to any tumour type provides a powerful 
tool for the analysis of the tumorigenic process. In order to make use of this, it is 
important to have available theoretical models to study the influence of number of stages 
on tumorigenic processes. In this chapter, we will establish a model in which up to 3 
stages are required to provide cellular malignant transformation. The stages are conceived 
as disruption of one or both p53 alleles, and an additional transformation event, which may
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be composite. Analysis of experiments using p53 transgenic mice may help to reveal 
properties of the third stage which is initially introduced as a 'black box'. It is important 
also that the model should be able to represent the statistics of tumorigenesis in embryonic 
as well as post-natal mice, since transgenic mice are exposed to increased risk of 
tumorigenesis from time of conception onwards.
In this chapter, we will establish stochastic models for spontaneously occurring 
tumorigenesis in a one-, two- or three-stage mutational process in both growing 
(embryonic) and steady-state (adult) target tissue and explore the general properties of 
these models. In particular, it is intended to determine how the various parameters of the 
models within a reasonable range of values, affect the time (age) distribution of appearance 
of tumours, which is the most straightforward experimental observation. It is also intended 
to investigate the effect on the time distribution of number of mutational stages required 
for malignant change.
3.2 Model structure
The essential features of the three-stage model (Figure 3.1) are:
(1) Target cells for the first stage of malignant transformation are the stem cells of each 
tissue. Stem cells are presumed to replicate or differentiate/die (such as apoptosis) and to 
follow Gompertz-exponential or "Gomp-ex" growth kinetics during embryonic and post­
natal development (see section 3.3 and 3.4). In the adult, the numbers of stem cells remain 
approximately steady-state (cellular loss rate balanced by cellular proliferation rate). Stem
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cells are assigned to the initial compartment of the model and denoted X0(t).
self-renewal
> differentiation/death
self-renewal
> differentiation/death
self-renewal
-> differentiation/death
self-renewal
* differentiation/death
1-stage mutant
2-stage mutant
Stem cell
Malignant cell
detectable tumour
Figure 3.1 A three-stage model for tumorigenesis
(2) At each cell division, a daughter cell has a probability Pj of experiencing the first 
mutation leading to malignant change. These 1-stage mutants are assigned to the next 
compartment of the model and denoted Xj(t). The 1-stage mutants are otherwise identical 
to stem cells. They are presumed to replicate or differentiate/die (such as apoptosis), and, 
in the embryo and post-natal development phase, follow Gomp-ex kinetics (see section 
3.3 and 3.4), in the adult the cellular proliferation rate is equal to the cellular loss rate. The 
1-stage mutants have no growth advantage.
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(3) At each cell division, a 1-stage daughter cell has a probability p2 of experiencing the 
second mutation leading to malignant change. These 2-stage mutants are assigned to the 
next compartment of the model and denoted X2(t). The 2-stage mutants are also otherwise 
identical to stem cells. They are presumed to replicate or differentiate/die (such as 
apoptosis), and, in the embryo and post-natal development phase, follow Gomp-ex kinetics 
(see section 3.3 and 3.4), in the adult the cellular proliferation rate is equal to the cellular 
loss rate. The 2-stage mutants have no growth advantage.
(4) At each cell division, a 2-stage daughter cell has a probability p3 of experiencing the 
third - and final - mutation leading to malignant change. These 3-stage mutants are 
assigned to the next compartment of the model and denoted X3(t). A 3-stage mutant is a 
malignant cell. The malignant cells do have a growth advantage over all other cells. Their 
cellular proliferation rate is assigned a higher value than their cellular death rate (in the 
model this is done by setting the loss rate to zero).
(5) The cell cycle time of the stem cells, 1-stage mutants and 2-stage mutants remains the 
same and is not influenced by the mutational events.
(6) Detection of a tumour is recorded when the malignant cell population reaches 106 cells, 
provided a minimum time delay of x0 has elapsed. This allows for vascularization and 
morphogenesis of the tumour as well as growth of the cell population number.
The 1-stage and 2-stage carcinogenesis models have the same structure as the 3-stage 
model described above. They differ only in the number of mutational steps assumed 
necessary for malignant change.
3.3 Cell kinetic model for cell proliferation during mouse development
It is already known that growth of the whole mouse from conception onwards can be 
empirically described as initially following an exponential growth pattern which gives way 
to a Gompertzian pattern after some critical cell number Nc has reached, i.e., a Gompertz- 
exponential or Gomp-ex growth model (Wheldon, 1988), and it is reasonable to suppose 
that the various cell populations follow the same general pattern. Therefore if we consider 
a cell population N(t) we have, for the Gomp-ex growth model described by the piecewise 
continuous differential equation
J _  = I  *  m
N(t) dt 1 a - b  * ln[—A_L]
C
for initial growth from a single cell with Tc=ln(Nc)/a, where a represents the initial specific 
growth rate of the stem cell population (for N=1 when t=0) and b is the specific growth 
rate retardative parameter in the Gompertz equation.
However this formulation does not explicitly incorporate the cell division rate, which is 
important if mutational events occur preferentially in cells undergoing division. We need 
a cell kinetic model which explicitly includes the rate of cell division and also the rate of 
cell loss, but which gives the overall growth of the cell population to be same as for the 
Gompertz function. This problem was previously considered by Wheldon (1988) and the 
approach used here is similar to that analysis. A model which fits the stated requirements 
is
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t < T
C
t £  T
(3.1)
1 dN(t) _ 0.693 A m ]  - L
N(t) dt t (3.2)
where tc is the cycle time of proliferating cells, f[N(t)] is a function giving the proportion 
of cells proliferating at any time (the growth fraction) and L is a parameter giving the 
(constant) loss rate from population.
If we compare (3.1) and (3.2) we see that the new model will be identical to the Gomp-ex 
equation provided
This provides the number of cells in the growth fraction as a function of the total cell 
number. We then have
a +L t < Tc
A m ]  = 0.693 t > TC
(3.3)
Number of cells in cycle = f[N(t)]*N(t)
Rate of cell 
devision
a + L t<T,
For the three-stage model, N(t)=X0(t)+X1(t)+X2(t) and the numbers of stem cells, 1-stage 
mutants and 2-stage mutants in cycle are f[N(t)]*X0(t), f[N(t)]*X,(t) and f[N(t)]*X2(t), 
respectively. The same approach is used as for the two-stage model.
3.4 Outline of the simulation
The behaviour of a set of cells is followed using discrete events simulations (Maisel and 
Gnugnoli, 1972) in which the evolution of the population of cells is updated at each cell 
division. The simulation proceeds until a detectable tumour is generated, i.e. the population 
of malignant cells reaches the number 106 which corresponds to the smallest detectable 
tumour. Simulations were terminated by 600 days (see appendix 3).
3.4.1 Cellular behaviour at each division
(1) Stem cells: at each cell division, one stem cell may divide into two stem cells with 
probability a 0(t); may be lost with probability P0(t); may divide into one stem or lost cell 
and one 1-stage mutant with probability Pj(t); or may divide into one stem cell and one 
lost cell with probability y0(t) (Figure 3.2 (a)). The parameters a 0(t), P0(t), p^t) and y0(t) 
satisfy
Oo(t)+Po(t)+p, (t)-‘-y0(t)=i.
The numbers of cells undergoing these processes conform to a multinomial distribution 
(approximate Poisson or normal distribution when the number of stem cells is very large).
(2) 1-stage and 2-stage mutants: these cells have the same behaviour as stem cells (Figure
3.2 (b) & (c)). The rate parameters for 1-stage mutants are denoted a^ t), P](t), p2(t) and 
yj(t); those for 2-stage mutants are denoted oc^t), P2(t), p3(t) and y2(t), respectively. The 
numerical values of these parameters are the same as those of stem cells.
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(a) The behaviour of stem cells (SC) at each cell division
—  sc -- Ml -- Ml ---- D
sc— sc— sc— sc— sc—
—  sc —  sc -- D -- D
(b) The behaviour of 1-stage mutants (Ml) at each cell division
-- Ml -- M2 -- M2 ---- D
Ml-- Ml-- Ml-- Ml-- Ml--
-- Ml -- Ml -- D -- D
(c) The behaviour of 2-stage mutants (M2) at each cell division
-- M2 -- MC -- MC ---- D
M2-- M2-- M2-- M2-- M2--
-- M2 --  M2 -- D -- D
(d) The behaviour of malignant cells (MC) at each division
-- MC ---- D -- MCMC-- MC-- MC--
-- MC -- D -- D D denotes differentiation/death
Figure 3.2 The behaviour of stem cells and stem cell mutants
(3) Malignant cells: at each cell division, one malignant cell may divide into two malignant 
cells with probability cc^t); may be lost with probability p3(t); or may divide into one 
malignant cell and one lost cell with probability y3(t) (Figure 3.2 (d)). The parameters 
cc^t), P3(t) and y3(t) satisfy
a 3(t)+p3(t)+y3(t)=l.
The numbers of cells undergoing these events again conform to a multinomial distribution 
(approximate Poisson or normal distribution when the number of malignant cells is very 
large).
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In the simulation study, the parameter values are 
a = 1.063 day'1 
b = 0.231 day'1 
tc = 0.4 day 
L = 0.347 day'1 
Nc = 106 i.e. Tc= 13 days 
chosen to be representative of cell kinetics in the developing mouse. The population 
achieves 35% of its final value (~ 108 cells) by 20 days (time of birth). The final steady 
state value corresponds to the number of target cells in a representative tissue in the adult 
mice (eg bone marrow or epidermis).
Po(t) = L*tc ,
a + L t<13 days
<*o(t) = tc* J
1 a e‘b(t'13)+ L t>13 days
<*i(t) = otaCt) = a 0(t) and p,(t) = p2(t) = p0(t)
P](t), p2(t) and p3(t) are constant and varied, and
a 3(t) is constant and equals to a ,(tT), where tj- is time when malignant cell arose 
P3(t)= 0.
Where the time-dependence of a 0(t) represents the slowing of cell division as embronic 
growth proceeds (see section 3.2).
3.4.2 Generation of random variables
The pseudo-random number generator was described by Wichmann and Hill (1982). The 
methods for generating the binomial, multinomial, Poisson and normal distribution 
variables are given by Devroye (1986).
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3.4 Results
Each simulation begins with a single cell in the initial compartment and no cells in the 
others, i.e., the simulation follows growth and development from a fertilized ovum. The 
model structure is applicable to any mammalian species but kinetic parameters were 
initially chosen to represent mouse development. For each set of values of the parameters, 
the simulation repeats 1000 times. A useful figure of merit in analysing simulation data 
is the T50 value: the time until tumours are detected in 50% of the individuals. In situations 
where tumour incidence is low, the T5 value is used instead.
3.4.1 General findings
After 70-day growth from conception, the total cell population in the target tissue remains 
approximately steady-state (Figure 3.3). Interestingly, a detectable tumour does not appear 
in any mice until a few days after birth (assuming 20 days gestation for mice) even for the 
one-stage model with a high mutation rate of 10‘4 (Figure 3.4). When the mutation rate at 
each stage is low, for the 2-stage or 3-stage model, tumours are detected only in a small 
proportion of mice, however long the simulation time.
The most important parameters affecting the age-incidence of tumour appearance are the 
mutation rate at each stage, the steady-state number of target cells and the number of 
mutational events necessary for malignant change.
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Figure 3.3 Kinetics of growth of a representative mouse tissue from conception to 
maturity with standard deviations shown at low, intermediate and high cell populations.
3.4.2 Mutation rate
For all simulations, increasing mutation rate leads to a steeper and left-shifted (earlier) age- 
incidence curve (Figure 3.4). For lower mutation rates, the T50 value is steeply decreasing 
with mutation rate; at higher values the relationship tends to flatten out (Figure 3.5).
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(Figure 3.4 to be continued)
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( C ) Three-stage model
Figure 3.4 Kinetics of appearance of tumours in mice. (A) one-stage model; (B) two-stage 
model; (C) three-stage model. The graphs are labelled by the value of spontaneous 
mutation rate. The mutation rates in each stage are same and are labeled in graphics.
3.4.3 Target cell number
For all models the T50 value is less for higher steady-state target cell number. However the 
steepness of this relationship is strongly dependent on the mutation rate. With low values 
of mutation rate, the T50 value declines rapidly with increasing target cell number; at higher 
values this relationship also tends to flatten out (Figure 3.6).
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Figure 3.5 Time to appearance of first tumour in 50% mice (T50) and 5% mice (T5). The 
mutation rates in each stage are same.
3.4.4 Mutational events
With increasing numbers of mutational events required (1 to 3) the age-incidence curve 
moves to the right (later) (Figure 3.4) and the T50 value increases. However the difference 
is less marked for higher mutation rates (Figure 3.5).
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Figure 3.6 Time to appearance of the first tumour in 50% mice (T50). (A) one-stage 
model; (B) two-stage model; (C) three-stage model. The mutation rates in each stage are 
same.
3.5 Discussion
Besides the features that have been incorporated in early models considered by Moolgavkar 
and colleagues (1979, 1981), the models used in this study take into account the number 
of cells in cycle (growth fraction) during mouse development. This is important because 
most tumours probably originate from these renewing cell populations (Buick and Tannock, 
1992). We assume that the growth fraction is a function of the total cell number. In the 
embryo, most cells are in cycle whereas in the adult, in which net growth has ceased, only 
a small proportion of the cells are actively proliferating to balance the cell loss.
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There is no doubt that carcinogenesis is a multistage process due to sequential mutations 
(or equivalent epigenetic events) of specific genes. The number of mutations required for 
genesis of specific cancers is not definitely known, but is unlikely to be fewer than two 
and may be as many as ten (Renan, 1993). Here, we have developed one- two- and three- 
stage models in order to study some general features. As expected, larger numbers of 
mutational stages lead to later appearances of tumours, but the dependence of latency on 
stages is most clearly seen at lower than higher mutation rates. This observation may be 
important in future work.
Albanes and Winick (1988) proposed that, within any one species, cancer risk is 
proportional to both cell number and the rate of cell division. Carcinogenesis can be 
increased by either increasing the number of cells at risk or increasing the mitotic activity 
of a tissue. Our studies have also shown the more tumours occur with increasing the target 
cell number, however this effect is influenced by the spontaneous mutation rate and 
number of mutational events required for malignant transformation.
In general, the parameters examined, i.e., mutation rate, target cell number and number of 
mutational events, affected the age-incidence curves in the expected fashion. However, a 
striking observation was that the effects of each of the parameters were less dramatic at 
higher than lower mutation rates. The mutation rate itself was less influential once a higher 
range of mutation rates was reached. Physically, this may be because cells accumulate 
rapidly in the malignant cell compartment at higher mutation rates and the cellular growth 
rate becomes the most important parameter. This observation may be especially important 
for the analysis of tumorigenesis in p53 deficient transgenic mice since it is presently 
believed that p53 inactivation may result in genetic instability, i.e., in higher mutation rates
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applicable to the remaining stages of tumorigenesis (Livingstone et al, 1992; Yin et al; 
1992).
The present findings also suggest that the role of target cell number (as measured by its 
final steady-state value) is also most clearly seen at lower rather than at higher mutation 
rates. This could be applicable to experiments in which (for example) variable numbers of 
p53 deficient bone marrow stem cells are transplanted into wild-type mice, and when target 
cell number is effectively changed by killing by radiation and drugs.
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Chapter 4
A Multistage Model for Radiation Tumorigenesis in 
p53 Deficient Mice: the Effect of Single Doses of
Radiation
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4.1 Introduction
Radiation produces a wide spectrum of lesions in the DNA of cells (Hutchinson, 1993). 
These lesions may be repaired or misrepaired (Elkind, 1984; Price, 1993). The lack of 
repair, or misrepair, can lead to chromosomal aberration, further inducing mutations and 
malignant transformation, and eventually giving rise to tumours.
In order to assess the quantitative cancer risk of exposure to radiation, many theoretical 
models have been developed to construct the dose-response relationship for tumorigenesis 
(UNSCEAR, 1986). These models, however, are often empirical rather than incorporating 
the biological mechanisms known to exist. In this chapter, it is intended to incorporate the 
effects of irradiation, i.e., cell killing and mutation, in a model established for spontaneous 
tumorigenesis in Chapter 3 and to investigate the carcinogenic effect of single doses of 
radiation. In particular, it is intended to explore how age at exposure, spontaneous mutation 
rate and number of mutational events required for neoplastic transformation influence the 
appearance of tumours and the dose-response relationship of tumour latency. The model 
will be used to predict the optimal time (age) of radiation for tumorigenesis.
4.2 Model and assumptions
Radiation tumorigenesis, like spontaneous tumorigenesis, is multi-stage (Cox, 1994; Fry 
et al., 1982). The stages of radiation tumorigenesis are believed to be same as those of 
spontaneous tumorigenesis. The role of radiation in this whole process is induction,
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producing mutations, and acceleration, shortening the latency period. A major effect of 
radiation is the deletion of DNA sequences, which frequently result in cell death. In 
particular, clonogenic cells —  cells which are usually capable of prolonged proliferation 
—  may be sterilised, or deprived of their proliferative ability. In radiobiology, this is 
considered synonymous with 'cell killing'. However, some cells will survive and may have 
undergone mutations predisposing to malignancy, represented here as the migration of cells 
from their current stage to next one.
As discussed in Chapter 3, we will consider a 3-stage tumorigenesis model which requires 
inactivation of each of two p53 alleles and one other mutational step. The third step is 
envisaged as a 'black box' and may prove to be composite. The availability of p53 deficient 
transgenic mice (heterozygote and homozygote null) means that the number of stages 
required for tumorigensis may be reduced from 3 to 2 or 1, facilitating study of the 
tumorigenic process. The structure of three-stage radiation tumorigenesis model is 
schematically represented in Figure 4.1.
4.2.1 General assumptions
For the model shown in Figure 4.1, it is assumed that, before exposure to single dose 
radiation, the tumorigenic process is spontaneous, so the features of model is same as 
described in section 3.2 in Chapter 3. At time zero, corresponding to fertilization, only a 
single stem cell (fertilized ovum) is present. Post radiation, cells at different stages may 
be killed or survive. Amongst surviving cells, some may be migrated to the next 
mutational stage. Suppose that there are no surviving cells which experience two 
tumorigenic mutations by radiation at single exposure. The total cell population is reduced 
by the killing effect of radiation although repopulation by surviving cells will occur.
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Figure 4.1 Three-stage model for radiation tumorigenesis
The one- and two-stage radiation tumorigenesis model have the same structure as the three- 
stage model. They differ only in the number of mutational events necessary for malignant 
change.
4.2.2 Cell surviving fraction
Numerous radiobiological models, which predict the probability of cell survival post
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radiation, have been proposed, such as linear-quadratic model (Hall, 1994), repair-misrepair 
(RMR) model (Tobias 1985), lethal-potentially lethal (LPL) model (Curtis, 1986), etc.. In 
this study, we will make use of the linear-quadratic model, for which the probability of cell 
survival (S) is predicted as
S=exp{-(a, D+ ^  D2)} 
where D is a single dose, and aj and a^ , are cell survival parameters. In this study we will 
assume and a^ , values which are typical of cells growing exponentially in culture (at =0.3 
Gy'1 and a2=0.03 Gy'2) (Leenhouts and Chadwick, 1989).
Also, we assume that stem cells, 1-stage mutants, 2-stage mutants and malignant cells have 
the same probability of surviving post radiation, i.e., the malignancy-predisposing mutation 
does not alter the radiosensitivity of the cells.
4.2.3 Mutation frequency
The dose response relationship for tumorigenic mutation is not well established. However, 
it is reasonable that the probability that any cell carries a mutation of given (tumorigenic) 
type should be approximately linear at lower doses, but asymptotic to unity at higher dose. 
Suppose that mutation frequency (M) per surviving cell is given by
M=l-exp{-q D}
where D is a single dose, and q=0.001 Gy'1 is a reasonable parameter value (from study 
by Leenhouts and Chadwick, 1989). Notice that for small values of q and lower dose,
l-exp{-q D}~ q D
i.e., mutation frequency is approximately linear with dose in the low dose range.
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We assume that the mutation frequency of surviving stem cells, surviving 1-stage mutants 
and surviving 2-stage mutants is the same (Mj=M2=M3=M) , i.e., no change in genomic 
stability as a result of acquiring the first mutations (in future studies, we shall relax this 
condition).
4.2.3 Repopulation process
The cell population is reduced because of cell killing. The repopulation process is assumed 
to be same as that of normal development (Figure 4.2), i.e., an exponential growth process 
when the population is well below steady-state value, followed by Gompertzian growth as 
the original steady-stae value is approached (see Section 3.3 in Chapter 3).
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Figure 4.2 Kinetics of repopulation following radiation: this is initially exponential but 
becomes Gompertzian as population number increases and recovers with similar kinetics 
following single dose radiation.
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4.3 Computer simulation study
In this analysis, radiation-induced tumorigenesis is represented by a pulse, or perturbation 
in numbers of cells at various stages, due to the brief (effectively instantaneous) radiation 
exposure (Figure 4.2). Post radiation, the numbers of cells that survive and surviving cells 
that undergo mutation are simulated as a Poisson distribution with expectation XS and YM, 
respectively, where X and Y represent the number of cells just before radiation and the 
number of surviving cells at each stage, S and M are given in Section 4.2.2 and 4.2.3, 
respectively. The whole process is simulated as described in Chapter 3. The value of the 
parameters is same as that given in Chapter 3. For each set of parameters, 1000 cases are 
simulated. T50, i.e the time until tumours are detected in 50% of the individuals, is used 
to present the dose-response relationship.
In this study, we have used a computer simulation model rather than seeking analytic 
results as can be done for simpler models of this type. The advantage of the computer 
simulation approach is its generality. Although used only for single dose irradiation here, 
we will in future consider more complex patterns of irradiation for which analytic solutions 
would not be possible.
4.3.1 General findings
Usually, a single dose of radiation results in earlier appearance of tumours, but when the 
spontaneous mutation rate is higher and age at exposure is late, irradiation does not 
noticeably decrease the tumour latency (Figure 4.3, 4.4, 4.5 and 4.6) despite increasing the
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number of mutants. When tumorigenesis is 2- or 3-stage with lower values of the 
spontaneous mutation rate at each stage, tumours are detected only in a small proportion 
of mice. For example, if tumorigenesis is 3-stage with a spontaneous mutation rate of 10‘6 
at each gene locus per cell division at each stage, only about 0.3% of the mice have 
tumours during a 600-day period after 6 Gy irradiation is given at neonatal age. This 
theoretical prediction is consistent with a very low rate of tumorigenesis for wild type mice 
(with intact p53 alleles); on the model this means three stages are required for 
transformation (Kemp et al., 1994).
4.3.2 Dose-tumour-latency relationships
The dose-tumour-latency relationships for tumorigenesis post single whole-body exposure 
are influenced by age at exposure, the spontaneous mutation rate and the number of 
mutational events required for malignant transformation (Figure 4.4), but they may be 
grouped under three categories of relationship:
(1) T50 decreases with increasing dose down to a minimum, with an increase following that
minimum (the increase is due to the increasing role of cell killing);
(2) T50 is flat with increasing dose;
(3) T50 increases with increasing dose.
Contrary to 'common sense' expectation, the tumour frequency does not increase as a 
simple function of dose in all cases. Only in a limited class of scenarios would be a clear 
dose-response relationship be observable in experimental studies.
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Figure 4.3 Kinetics of appearance of tumours in mice induced by single dose radiation. 
SMR: spontaneous mutation rate ( per generation per cell)
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4.3.3 Age at exposure
In the simulation study, the T50 value decreases with increasing age at exposure down to 
a minimum, with a slight increase following that minimum for one-stage tumorigenesis 
(Figure 4.5, A to F). However, for two- and three-stage tumorigenesis, this appearance only 
occurs at higher values of spontaneous mutation rate. With lower values, T50 tends to 
flatten out (Figure 4 .5 ,1 to N).
In the following simulation, the spontaneous mutation rate was allowed to vary between 
stages. Interestingly, for 2- and 3-stage tumorigenesis, when the spontaneous mutation rate 
in the primary stage is lower, and in the later stages is higher, T50 increases with age at 
exposure (Figure 4.6, 1 A, IB ,..., & 1J). But, conversely, with higher spontaneous mutation 
rate in the primary stage and lower spontaneous mutation rate in later stages, the results 
are critically different for three-stage tumorigenesis, T50 always decreases with increasing 
age at exposure (Figure 4.6, 2J), whereas for two-stage tumorigensis, T50 rapidly decreases 
down to a minimum, then increases (Figure 4.6, 2A, 2B, ..., & 21). These results suggest 
that the spontaneous mutation rate in later stages may be much more important.
The optimal time (age) of irradiation, i.e., age at exposure when the minimum value of T50 
is reached, is in the neonatal stage and slightly varies with dose, spontaneous mutation rate 
and number of mutations required for tumorigenesis. When mutation rate is very low in 
each stage of two-stage and three-stage model, it is difficult to tell the optimal age of 
radiation tumorigenesis.
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4.3.4 Spontaneous mutation rate: influence on dose-tumour-latency
For one-stage tumorigenesis, the most important thing is the growth of tumour to become 
overt, the spontaneous mutation rate does not seem to be important because many cells will 
transform by radiation even at low mutation rates, whereas, for two- or three-stage 
tumorigenesis, the steepness of the dose-tumour-latency relationship is strongly dependent 
on the spontaneous mutation rate. With low values of spontaneous mutation rate, the T50 
value declines rapidly with increasing dose in the lower dose regions; at higher values, the 
dose-response relationship tends to flatten out (Figure 4.4).
4.3.5 Number of mutational events
With a smaller number of mutational events, T50 is always lower (the latency period is 
shorter) and the steep portion of the dose-tumour-latency curve always comes earlier 
(Figure 4.4). However the difference is less marked for higher spontaneous mutation rates. 
Therefore, the number of stages is most important at low spontaneous mutation rate.
4.4 Discussion
We have established 1-, 2- and 3-stage stochastic models for radiation tumorigenesis and 
have shown that, in the majority of cases, a single dose of radiation usually results in 
earlier appearance of tumours, but with higher value of spontaneous mutation rate, there 
is no decrease in the tumour latency compared to spontaneous when age at exposure is
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later (Table 4.1). The reason may be that, while providing greater opportunity for tumour 
development, radiation kills tumour cells that are spontaneously converted. There exists a 
competition between induction and cell killing. Therefore, if it is found experimentally that 
the latency increases at low doses (0-4 Gy), this may indicate high spontaneous mutation 
rate and possibly low number of stages. This observation may allow us to understand why 
7-week-old p53 null mice exposed to a single of 4 Gy whole body y radiation did not 
experience decreased tumour latency although latency was decreased in irradiated p53 
deficient heterozgous mice (Kemp et al., 1994). It is presently believed that p53 
inactivation may result in genetic instability, i.e. in higher mutation rates applicable to the 
remaining stages of tumorigenesis (Livingstone et al., 1992; Yin et al., 1992). Thus, there 
may have been already tumours developing spontaneously, and irradiation would make 
little difference to time of appearance of the first one.
In the multistage theory of tumorigenesis, the events necessary to produce a tumour cell 
might occur spontaneously which means that they might accumulate with age. In fact, it 
has been found that the T50 value changes with age at exposure, but this relationship is 
influenced by the spontaneous mutation rate and number of mutational events required. 
With lower value of spontaneous mutation rate, for 2- and 3-stage tumorigenesis, there is 
no clear change in the value of T50 with age at exposure increasing.
When the spontaneous mutation rate in the primary stage is lower, and in the later stages 
is higher, radiation may mainly have effect on primary stages, it will be acting on the 
population of stem cells, whereas, with higher spontaneous mutation rate in the primary 
stage and lower spontaneous mutation rate in later stages, it may mainly have effect on the 
later stages, it will be acting on the population of the cells that have already reached an 
premalignant stage. So, in the former case, we observed that T50 increases with age at
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exposure, but in the latter case, T50 decreases with age at exposure, however, after a certain 
age, T50 increases with age at exposure, possibly because some malignant cells may have 
already arisen from stem cells, and these are then killed by radiation.
It has been found the forms of the dose-response relationships vary. The number of stages, 
spontaneous mutation rate and age at exposure are of importance in determining the shape 
of the dose-response curve. The dose-response relationship observed in a particular 
situation may be helpful in providing some mechanistic information about radiation 
tumorigenesis.
Table 4.1 Effect of radiation (0-4 Gy) on tumour latency
Age at radiation exposure Number of stages Latency
Low spontaneous mutation rate
early 1 i
2 i
3 4
late 1 4
2 4
3 4
High spontaneous mutation rate
early 1 4
2 4
3 4
late 1 t
2 t
3 4
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In conclusion, a single dose of radiation usually leads to earlier appearance of tumours, but 
such effects depend on age at exposure, the spontaneous mutation rate and the number of 
stages required for malignant change. The dose-response relationship has a steepness which 
is strongly dependent on age at exposure, the spontaneous mutation rate and the number 
of stages. The number of mutational events is most influential at low spontaneous mutation 
rate. The optimal time of irradiation for maximum yield of tumours in mice is predicted 
to be around time of birth and slightly changes with dose, spontaneous mutation rate and 
the number of mutational events. This information will be necessary for analysis and 
interpretation of experimental data on radiation-induced tumorigenesis in transgenic mice 
with p53 genetic abnormalities.
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Chapter 5
Tumour Multiplicity Analysis in p53 Deficient Mice
86
5.1 Introduction
As reviewed in Chapter 1, inherited p53 mutations in transgenic mice and in Li-Fraumeni 
human patients lead to significant increases in tumour incidence. However, although each 
somatic cell inherits the mutation with presumably millions of target cells at increased risk, 
the number of tumours that develop in each individual is usually quite small (Vogelstein, 
1990), i.e. there are no more than a few independent malignant clones, rather than the 
many which might have been expected. This observation led us to use the carcinogenesis 
model, which is extended from Chapter 3, to simulate tumour clone multiplicity in wild- 
type and p53 deficient transgenic mice.
The time taken for second and other tumours to occur after the first tumour has formed, 
i.e. the distribution of the lag between the first tumour and others, is also very important. 
If the lag between the first tumour and others were very long, the first tumour could result 
in mouse death (or humane sacrifice) before the second and other tumours could be 
detectable. This would lead to a gross underestimate of tumour clonality, if single-tumour 
bearing mice were to harbour additional undetected tumours at time of death.
In this chapter, it is firstly intended to generally investigate how the spontaneous mutation 
rate, number of target cells and the number of mutational events required for malignant 
transformation affect tumour multiplicity (i.e. number of independently-arising tumours) 
during the same period and the lag distribution between the first-appearing tumour and 
others.
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Later, we will study tumour multiplicity in wild type and p53 deficient mice, and show 
that multistage models in which inactivation of each p53 allele represents a distinct stage 
in a single pathway of tumorigenesis invariably predict excessively large numbers of 
tumours in both p53 deficient heterozygotes and homozygotes, allowing this category of 
model to be decisively rejected.
5.2 Mathematical modelling and computer simulation
The model of tumorigenesis, illustrated in Figure 5.1, is a k-stage model, which is 
generalised from the model in Chapter 3. So the features of this model are same as 
described in Section 3.2 of Chapter 3. Each stem cell at division may reproduce, die or 
differentiate, or experience a mutation advancing the cell to the next stage of the model. 
Cells experience these competing processes independently. Pre-malignant mutants are taken 
to follow the same self-limiting growth pattern as unmutated stem cells, i.e. the pre- 
malignant mutants have no growth advantage. However, each malignant cell, once it exists, 
follows an unrestrained growth pattern (linear birth-death process) until the tumour is large 
enough to be detectable (106 cells).
The precise value of the expected number of tumours is not analytically expressible and 
has to be calculated numerically (see appendix 1). The exact distribution of number of 
tumours is also not describable analytically, although an approximation to the distribution 
can be obtained (Sherman et al, 1994).
We predicted tumour multiplicity and explored the distribution of lag time between the
first-appearing tumour and the detection of any others by using computer simulation, with 
the simulation continued to 600 days, i.e. close to mouse lifespan. The process of computer 
simulation will be divided into two stages, i.e. the conversion of a normal stem cell into 
a malignant cell and the growth of each malignant clone to form a tumour (See Appendix 
3). Ideally, each malignant cell should be followed separately, but this becomes prohibitive 
when the number of malignant cells generated is large. In that case, the detection (or not) 
of a tumour is simulated as a binomial distribution with the probability FD(s,600) that a 
tumour cell at time s is detectable as a tumour at or before 600 days and is obtained by 
Feller-Arley birth-death process (Tan, 1990), where s is the time at which the malignant 
cells are generated.
self-renewal
self-renewal
self-renewal
self-renewal
k-l
2-stage mutantl
Stem cell
k-l-stage mutant
mutant
differentiation/death
differentiation/death
differentiation/death
differentiation/death
Malignant cell
Detectable tumour
Figure 5.1 General structure of the multistage single path model.
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In our simulation, the growth kinetics of each cell and the value of parameters are as 
described in Chapter 3. 104 simulations were carried out for each choice of parameters in 
the models. The total number of malignant cells generated from stem cells and the total 
number of tumours detected during 600 days, the time of appearance of the first 10 
tumours are recorded for studying the distribution of the lag between the first-appearing 
and subsequent tumours.
5.3 General findings
5.3.1 Mutation rate
The mean number of tumours per mouse increases with mutation rate at each stage (Figure 
5.2). Furthermore, it is also shown that an increase in the spontaneous mutation rate results 
in a corresponding increase in the probability of more than one detectable tumour in a 
mouse (Figure 5.3).
5.3.2 Number of mutational events
With a smaller number of mutational stages required for malignant transformation, the 
mean number of tumours per mouse is always larger during the same period (Figure 5.4). 
Reduction of the number of mutational stages also results in a corresponding increase in 
the probability of more than one tumour. However, a large number of independent tumours 
appear together in a mouse only in the situation with few stages and high mutation rate.
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Figure 5.2 The relationship between the mean number of tumours and spontaneous 
mutation rate (SMR). (A) SMR are same in each stage; (B) SMR varied in each stage of 
two-stage tumorigenesis.
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Figure 5.3 The probability density of the number of tumours. (A) two-stage tumorigenesis;
(B) three-stage tumorigenesis; (C) four-stage tumorigenesis.
92
c_<DJD
1E+07
1E+06
1E+05
1E+04
1E+03
1E+02
1E+01
1E+00
IE-01
2 3
Number of Stages
Figure 5.4 The relationship between the mean number of tumours per mouse and the 
number of stages required for malignant transformation.
5.3.3 Number of target cells
For the all models, the mean number of tumours increases with the number of target cells 
(Figure 5.5). This relationship is shifted by spontaneous mutation rate and is influenced by 
the number of mutational events required for malignant transformation (Figure 5.5). These 
observations provide a possible experimental test of the model predictions. (For example, 
if variable numbers of p53 deficient bone marrow stem cells are transplanted into wild-type 
mice.)
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5.3.4 Distribution of the lag between the first and subsequent tumours
The distribution of lag time between the first and subsequent tumours is dependent on the 
spontaneous mutation rate and the number of mutational events required for malignant 
transformation (Figure 5.6). With a higher mutation rate and fewer mutational events, the 
distribution of lag always shifts left (Figure 5.6), that is the time difference between first 
tumour and others become shorter. This result indicates that, in this situation, many 
independently-arising tumours may appear together in a mouse.
5.4 Tumour multiplicity in p53 deficient mice
As shown in Chapter 3, tumorigenesis in p53 deficient mice is interpreted using the 
multistage model in which inactivation of each p53 allele represents a distinct stage. For 
wild-type genotypes, we have considered 3-stage, 4-stage and 5-stage models and have in 
each case chosen the mutation rate to match the tumour incidence (about 10%) observed 
experimentally (Donehower et al, 1995) in wild type mice by 600 days. The corresponding 
tumour incidences for p53 null heterozygous and p53 null homozygous mice may then be 
computed by subtracting 1 or 2 stages respectively without changing the mutation rate. For 
presentation, we have computed the tumour incidence by 80 weeks, and the mean number 
of tumours per mouse predicted to have appeared by 16 and 80 weeks, close to the 
observed median latency in p53'A and p53+/' mice, in each of these situations.
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Table 5.1 shows that 3, 4 and 5-stage models all predict the early development of large 
numbers of tumours in both p53+/* and p53'/_ mice. Although experimentally observed 
numbers of tumours will certainly be underestimates of the number destined to develop, 
it hardly seems possible that the predicted thousands of tumours could be reconciled with 
the typical observation of one or two. The corresponding age-incidence curves are shown 
in Figure 5.7 and demonstrate much faster tumour development predicted by the model for 
both p53 deficient genotypes than occurs in practice (The latent periods seen 
experimentally for p53 deficient mice are also shown in figure 5.7 for comparison). This 
discrepancy has been found to occur for all combinations of model parameters giving 10% 
lifetime incidence of tumours in wild-type mice; it appears to be a robust feature of this 
class of model. We have concluded that it is not possible to accommodate data on tumour 
incidence in wild type and p53 deficient mice by the classical multistage single-path 
model.
Table 5.1 Tumour incidences in mice of different genotypes as predicted by 3, 4 and 5 
stage single path models. The mutation rates were chosen to match tumour incidence (ie 
fraction of mice developing tumours) observed experimentally in wild type mice. In this 
scenario, all tumours develop by a route involving p53 inactivation.
Genotype Experimental
data
3-Stage Model
(M u ta t io n  ra te = 7 .5  x  I # 4)  
T u m o u r s  /m o u se
(S E )*
4-Stage Model
(M u ta t io n  r a t e  = 5 x  Iff*) 
T u m o u r s  /m o u se
(SE)*
5-Stage Model
M u ta t io n  ra te = 1 .6 5  x  10*) 
T u m o u r s  /m o u se
(S E )*
1 6  w e e k s  8 0  w e e k s 1 6  w e e k s 8 0  w e e k s 1 6  w e e k s 8 0  w e e k s
p5 3 +H' 0 0.08
p 5 3 +/- 0 0.53
$53''- 0 1.00
♦ SE = standard error of mean number i
0.002 0.12 0.003
(0.0007) (0.006) (0.0001)
6.8 1.9xl02 0.26
(0.26) (1.8) (0.02)
3.3x10* 1.7xl03 5.5xl02
(1.6xl02) (8.4xl02) (9.7)
per mouse
0.09 0 0.2
(0.005) (0) (0.007)
45 0.03 19
(0.55) (0.004) (0.17)
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Figure 5.7 Predicted age-incidence pattern of tumour development in mice of three 
genotypes for (A) 3-, (B) 4-, and (C) 5-stage single path models. In each case the mutation 
rates have been chosen to match tumour incidence observed experimentally in wild type 
mice by 80 weeks; the models then predict excessively rapid development of tumours in 
both p53 deficient genotypes. The broken lines in the diagrams show the incidence of 
experimental tumours (data from Donehower et al (1995), dashed line).
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5.5 Discussion
Computer simulation studies of tumour multiplicity by the multistage model has been 
carried out. In these studies, the issue of the tumours within tumours (i.e. intratumoural 
multiclonality) was not taken into account, however, this is not likely to be an important 
issue in practice.
If the rate of death (including apoptosis, differentiation, etc.), i.e. cell loss, is greater than 
zero, then there is non-zero probability that a tumour cell will become extinct without 
giving rise to a detectable tumour. Also, some of tumour cells may not have enough time 
to grow into a detectable tumour before the host is dead. This could lead to a gross 
underestimate of tumour multiplicity (Table 5.2).
The simulation studies generally show that the mean number of tumours per mouse 
strongly depends on the spontaneous mutation rate, the number of mutational events 
required for malignant transformation, and number of target cells. However, there is a 
considerable stochastic variation around this mean (Table 5.2), and this variation is also 
dependent on the spontaneous mutation rate, and the number of mutational events (Table 
5.2).
The analysis has demonstrated a fundamental problem in the application of the classic 
multistage model to spontaneous tumorigenesis in p53 deficient mice. On a multistage 
model, with a single pathway of tumorigenesis, the reduction in stage number by one, 
resulting from germ line inheritance of one of the tumorigenic mutations, without change 
of mutation rate, results in a marked increase in predicted tumour frequency. Transgenic
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mice have provided a unique opportunity to test the prediction that the inheritance of two 
tumorigenic mutations (inactivated p53 alleles), corresponding to a reduction in stage 
number by two, would produce an astronomical number of tumours per mouse. Our 
analysis shows that this prediction applies for up to five stages being required for 
tumorigenesis in wild type mice.
Table 5.2 The mean number of tumour cells arising from stem cells and the mean number 
of tumours
Number of Stages Spontaneous 
Mutation Rate
Mean Number of 
Tumour Cells (SD)*
Mean Number of 
Tumours (SD)*
1 io-4 2.53x106(1.15x104) 2.35xl0°(l .07x10°)
10‘5 2.63x105(1.24x105) 2.44x 105(1.16x105)
IO'6 2.61x104(1.21x104) 2.42xl04(1.12xl04)
10‘7 2.56x103(1.21x103) 2.38xl03(1.12xl03)
IO'8 2.60*10J(1.23xl02) 2.41xl02(1.14xl02)
IO'9 2.55xl0‘(1.30xl01) 2.37xl0'(1.22xl0')
2 io -4 4.29x104(2.17x104) 3.74x104(1.91x104)
10 s 4.25x102(2.77xl 02) 3.67xl02(1.92xl02)
IO'6 4.29xl0°(3.29x10°) 3.63xl0°(3.51xl0°)
IO'7 4.20x1 0-2(2.30x10'') 2.80xl0-2(1.82xl0-')
3 10"1 4.64x 102(2.69xl 02) 3.75 x 102(2.23xl 02)
IO'5 4.54xl0'1(7.67xl0'1) 3.72x10''(6.69xl0'')
4 10-4 3.38xl0°(3.01xl0°) 2.49x 10°(2.45xl 0°)
IO'5 2.00xl0'3(4.50xl0'2) 2.00x10‘3(4.50x10'2)
* The figure in brackets is the standard deviation.
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We may argue that by the first-appearing tumour causing the death (or humane 
sacrifice) of mice, the other tumours do not have the chance to appear, but it seems not 
to be true. From the distribution of lag times between the first-appearing tumour and 
the others, we predict that many tumours will occur in p53*/_ mice within few days even 
when the tumorigenesis in the wild-type mice is assumed to require 5 mutational stages 
(Figure 5.8).
600
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Lag between 1st and 5th tumour (davs)
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400
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200  -
100 -
7020 30 40 50 60 80 900 10
Lag between 1st and 10th tumour (davs)
( B )
Figure 5.8 The distribution of the lag between 1st tumour and others in p53_/" mice as 
predicted by the 5-stage tumorigenesis model. (A) 1st and 5th, (B) 1st and 10th
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This difficulty has been recognised previously. In 1990, Vogelstein commenting on tumour 
incidence in human Li-Fraumeni patients (who inherit a single defective p53 allele) posed 
the question ‘Why don’t these patients develop more tumours?’ and commented ‘Given the 
diverse tumours occurring in Li-Fraumeni patients it would seem that many human cell 
types are susceptible to the effect of inherited p53 mutations; yet the median age of tumour 
development is over 30 years and the median number of lifetime tumours is less than two' 
(Vogelstein 1990). Vogelstein’s paradox also occurs for the double-defect p53‘;’ mice, 
which still show no more than a few tumours per mouse, although thousands would be 
predicted. Two categories of explanation for this paradox will be given in Chapter 7 and 
8 respectively.
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Chapter 6
Effect of Radiation on Tumour Multiplicity in p53
Deficient Mice
106
6.1 Introduction
In the previous chapter, we have shown that the number of events required for malignant 
transformation, the spontaneous mutation rate, and number of target cells influence the 
tumour multiplicity. In this chapter, we incorporate the effect of radiation, i.e., cell killing 
and mutation induction, into the model described in Chapter 5. In general, it is intended 
to explore:
(1) The dose-tumour-multiplicity relationship;
(2) Time of appearance of 1st, 2nd, and subsequent tumours;
(3) How age at exposure, the spontaneous mutation rate and the number of mutational 
events required for malignant transformation influence the dose-tumour-multiplicity 
relationship and the distribution of times of appearance of tumours.
Finally, we will consider the situation where there is a certain background incidence of 
tumorigenesis in p53 wild type mice (as we discussed in chapter 5) and a single dose 
exposure is introduced, and we will study tumour multiplicity in wild-type and p53 
deficient mice.
6.2 Modelling considerations
Figure 6.1 shows the structure of the k-stage model for radiation tumorigenesis, which is 
generalized from the model presented in Chapter 4. Before exposure to a single dose of 
radiation, the tumorigenic process is spontaneous. Post radiation, the cells (normal stem
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cells, 1-stage mutants, ..., k-1-stage mutants, and malignant cells) may survive or may be 
killed. Amongst the surviving cells (normal stem cells, 1-stage mutants, ..., k-l-stage 
mutants), some may undergo tumorigenic mutation produced by radiation.
self-renewal
differentiation/death
Radiation-inducedSpontaneous p.
self-renewal
differentiation/ death
Radiation-inducedSpontaneous P2
self-renewal
differentiation/death
Radiation-inducedSpontaneous P3
j Radiation-inducedSpontaneous Pfc}
self-renewal
differentiation/ death
i Radiation-inducedSpontaneous p
k-l-stage mutant
Malignant cell
1-stage mutant
Stem cell
2-stage mutantl
Detectable tumour
Figure 6.1 Structure of k-stage model for radiation tumorigenesis.
The tumour multiplicity is predicted by computer simulation, with the simulation continued 
to 600 days. The process of computer simulation is divided into two stages, i.e. conversion 
of a normal stem cell into a malignant cell and growth of each malignant cell clone to 
form a tumour. Each stage is affected by radiation. When exposure to a single dose of
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radiation occurs, it is required to find the number of cells killed and the number of cells 
which have undergone tumorigenic mutation (both radiation-induced and spontaneous). 
These numbers are simulated as a Poisson distribution, where the probability of cell 
survival is predicted by the linear-quadratic model, and the probability that any surviving 
cell carries a tumorigenic mutation is approximately linear at lower doses (details referred 
to Chapter 4).
6.3 General findings
The values of most parameters in the model are the same as stated in Chapter 4. For each 
set of parameters, 104 simulations were carried out. The mean number of tumours per 
mouse and T50 (the time until the 1st tumours, 2nd tumours, etc. are detected in 50% 
mice) are used to present the simulation results.
6.3.1 Dose-tumour-multiplicity relationship
In general, the dose-tumour-multiplicity relationship is strongly dependent on the number 
of mutational events required for malignant transformation, the spontaneous mutation rate, 
and age at exposure. The mean number of tumours per mouse initially increases with 
irradiation dose, reaches a maximum, and then decreases (Figure 6.2). However, when the 
exposure is given post-natally, the multiplicity has not reached the maximum by 4 Gy (at 
which dose the simulations were stopped) except in the case of the one-stage model 
(Figure 6.2).
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Figure 6.2 Dose-tumour-clonality response curve. (A) one-stage model; 
(B) two-stage model; (C) three-stage model; and (D) four-stage model
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It has also been found that exposure to a single dose of radiation results in a corresponding 
increase in the probability of more than one tumour in a mouse (Figure 6.3). Very 
interestingly, lower doses (such as 1 Gy) always increase this probability (Figure 6.3 A l- 
A4 and B1-B4) whatever the time of irradiation, whereas, for pre-natal exposure, with 
higher value of spontaneous mutation rate, the higher doses reduce this probability (Figure 
6.3 C1-C4 and D1-D4), which is considerably influenced by age at irradiation. These 
different observations provide a possible experimental test of the model predictions.
Figure 6.3 also shows that the number of tumours per mouse has a large variation, which 
is dependent on the number of mutational events required for malignant transformation, the 
spontaneous mutation rate, the dose of irradiation, and age at irradiation. Such variation 
reduces with the increase in the number of mutational events, and with decrease in the 
spontaneous mutation rate and dose (Figure 6.3).
6.3.2 Times of tumour appearance
The time of the first, second and subsequent tumour appearance is strongly dependent on 
the number of mutational events required for malignant transformation and the spontaneous 
mutation rate. It is also influenced by the dose of radiation and age at exposure (Figure 
6.4). With higher values of spontaneous mutation rate, for pre-natal exposure, higher doses 
of radiation do not accelerate tumour appearance, but lower doses do shorten the latency 
of tumour appearance (Figure 6.4). Interestingly, with the smaller number of mutational 
events and higher value of the spontaneous mutation rate, when the radiation is given at 
older age, the time of the first couple of tumours appearing does not shorten, but the time 
to appearance of subsequent tumours shortens (Figure 6.4 B3). This may be a consequence 
of radiation cell killing competing with tumorigenesis.
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(Figure 6.4 to be continued)
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Four-stage model
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Figure 6.4 Time to appearance of 1st tumour, 2nd tumour,..., 10th tumour in 50% mice 
(T50). (Al)and (Bl) one-stage model; (A2) and (B2) two-stage model; (A3) and (B3) 
three-stage model; (A4) and (B4) four-stage model.
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Surprisingly, with higher values of the spontaneous mutation rate in one and two-stage 
models, when the exposure to radiation occurs at a late age (eg 50 days), the latency of 
the first ten tumours is longer than in the spontaneous situation (Figure 6.4 B1 and B2). 
This is probably also due to the effect of radiation cell killing.
With higher number of mutational events and lower spontaneous mutation rate, the time 
between the first and subsequent tumours is also shortened by radiation. This relationship 
is also dependent on dose and age at exposure (Figure 6.4).
6.3.3 Spontaneous mutation rate
The spontaneous mutation rate is a very important biological factor for the effect of 
radiation on tumour incidence, multiplicity and latency. With higher values of mutation 
rate, when radiation is given very early or very late, the mean number of tumours/mouse 
is reduced (Figure 6.5), and the latency is prolonged by higher doses, especially for a small 
number of mutational events (Figure 6.2).
6.3.4 Number of mutational events
The number of mutational events required for malignant transformation is also a very 
important biological factor for the effect of radiation on tumour incidence, multiplicity and 
latency. With larger number of mutational events, the increase in tumour incidence and the 
mean number of tumours/mouse is not much increased by radiation (Figure 6.5), but the 
latency is shortened, especially when the spontaneous mutation rate is lower (Figure 6.2).
120
6.3.5 Age at exposure
Very interestingly, the effect of radiation on tumour multiplicity is very different between 
the cases of pre-natal and post-natal exposure (Figure 6.5). For single-dose pre-natal 
irradiation, the mean number of tumours per mouse decreases with dose, whereas when 
exposure is post-natal, the mean number of tumours per mouse increases with doses and 
does not reach the maximum by 4 Gy (except in the case of one-stage tumorigenesis) 
(Figure 6.2 (B), (C) and (D); and Figure 6.5).
The other interesting thing is, (except for the one-stage model), the mean numbers of 
tumours per mouse do not change markedly with age at irradiation when the exposure is 
given post-natally (Figure 6.5 (A2-D2), (A3-D3) and (A4-D4)).
6.4 Tumour multiplicity in irradiated p53 deficient mice
We also consider the situation where there is a certain background incidence (about 10% 
as previously discussed) in p53 wild type mice by 600 days and a single dose exposure is 
introduced. The corresponding tumour incidence for p53+/' and p53'7' mice then follows by 
subtracting 1 or 2 stages respectively without changing the spontaneous mutation rate and 
radiation sensitivity (i.e. ignoring any separate effect of p53 status on mutation rate and 
radiosensitivity).
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Figure 6.6 and 6.7 shows that 3, 4 and 5-stage models all predict the early development 
of large numbers of tumours in both irradiated p53+/' and p53';* mice whatever the time of 
irradiation. Although the experimentally observed number of tumours will certainly be 
underestimates of the number destined to develop, it hardly seems possible that the 
predicted thousands of tumours could be reconciled with the observation of 1.623 tumours 
(23 tumours/14 mice) per p53‘;‘ mouse irradiated with 4 Gy at age of 6 days reported by 
Kemp et al (1994). This discrepancy has been found to occur for all combinations of 
model parameters giving 10% lifetime background incidence of tumours in wild type mice, 
and it appears to be a robust feature of this class of model. Again, we have concluded that 
it is not possible to accommodate data on tumour incidence in wild type and p53 deficient 
mice by the classical multistage single-path model in which inactivation of each p53 allele 
is represented as a distinct stage in the tumorigenic process.
6.5 Discussion
The analysis has demonstrated that the effect of radiation on tumour multiplicity is strongly 
dependent on the number of mutational events required for malignant transformation, the 
spontaneous mutation rate, and age at exposure (summary in Table 6.1). Also, the shape 
of the dose-tumour-multiplicity curve is determined by these factors.
The age-associated change in tumour multiplicity may be attributable to two major factors:
(1) the proliferative activity of the target cells during or post (or both) exposure to 
radiation, and (2) the number of cells at risk.
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Table 6.1 Effect of radiation (0-4 Gy) on tumour multiplicity
Age at exposure Number of stages Tumour multiplicity
Pre-natal 1 z* '..
2 /’’S.
3 z * '*
4 Z *'*
Post-natal 1 Z *'*
2 t
3 t
4 t
When the irradiation is given during the fetal period, the mean number of tumours in mice 
irradiated with higher doses is less than with lower doses. This result indicates that, when 
the number of cells at risk is smaller, with higher doses, more cells are killed, hence the 
likelihood of cells undergoing tumorigenic mutation is very small. On the contrary, with 
lower doses, fewer cells are killed, with the result that the likelihood of cells undergoing 
tumorigenic mutation is larger.
The latency of appearance of 1st, 2nd, 3rd, etc. tumour is also dependent on the number 
of mutational events, the spontaneous mutation rate, dose, and age at exposure (summary 
in Table 6.2). With a smaller number of mutational events and a higher value of the 
spontaneous mutation rate, when the radiation is given at older age, the time of appearance 
of the first few tumours is not shortened, but the time of the subsequent tumours is 
shortened. This could be because radiation kills some early spontaneous occurring tumours 
and induces the late occurring tumours. If true, this implies that these tumours which occur 
early in irradiated mice in this scenario are less likely to carry radiation-induced genomic
j
i
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lesions than those tumours occurring later.
Table 6.2 Effect of radiation (0-4 Gy) on tumour latency
Age at exposure Number of stages Tumour latency
first few tumours consequent tumours
Low spontaneous mutation rate
Pre-natal 1 4 4
2 4 4
3 4 4
4 4 4
Neonatal 1 4 4
2 4 4
3 4 4
4 4 4
Adult 1 4 4
2 4 4
3 4 4
4 4 4
High spontaneous mutation rate
Pre-natal 1
2
3 S./*
4
Neonatal 1 t t
2 t
3 4- 4
4 4- 4
Adult 1 t t
2 t t
3 t 4
4 4 4
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As in the previous chapter, the analysis has also demonstrated a fundamental problem in 
the application of the classic multistage model to radiation tumorigenesis in p53 deficient 
mice. On a single pathway multistage model of tumorigenesis, the reduction in stage 
number by one, without change of spontaneous mutation rate and radiation sensitivity, 
results in a marked increase in predicted tumour frequency, corresponding to a reduction 
in stage number by two, the number of tumours per mouse would be astronomical, no 
matter the time of exposure. In next two chapters, we will try to develop models which 
could account for this.
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Chapter 7
Multiple Pathways Model for Multistage 
Tumorigenesis in p53 Deficient Mice
132
7.1 Introduction
In previous chapters, the models have been restricted to a single series of events leading 
to carcinogenesis, i.e., a single pathway, which have been found to predict a large number 
of tumours in p53 null heterozygous and null homozygous mice. In fact, for human cancer, 
p53 mutations do not occur in all cases of any one type of cancer (see Table 1.5.2 in 
chapter 1), and not all tumours developing spontaneously in p53 heterozygous mice show 
loss of the remaining p53 allele (Harvey et al, 1993; Kemp et al, 1994). This implies that 
there exist one or more p53 independent pathways.
Recently, several authors have considered an extension of the multistage model which 
allows for the development of any type of tumour by alternative multistage pathways 
involving different sets of genes (Tan 1991; Sherman and Portier 1994). In the present 
context, this means that a proportion of tumours in wild type mice developing by pathways 
which are independent of p53 status would have the same probability of occurrence in p53- 
deficient mice. In order to investigate this, a multiple pathway model for multistage 
tumorigenesis has been constructed. It was intended to explore the relationship between 
the fraction f  of the tumours developing in wild-type mice by the p53 pathway and the 
tumour multiplicity in p53+/' and p53’;' mice and to determine whether the model is 
compatible with the experimental data or not.
7.2 Models and assumptions
Figure 7.1 displays a two-pathway multistage model of tumorigenesis. There are two
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possible routes for a normal cell to be transformed into a malignant cell, i.e. the p53 
mediated route and the p53-independent route. The essential features of each pathway are 
as described in section 3.2 of chapter 3.
p53 independent pathway (M-stage)Normal
Cell
Q JZL XU
death
pS3 mediated pathway (N-stage)
Malignant
Cell
Figure 7.1 General structure of the multipath/multistage model with p53 mediated andp53 
independent routes of tumorigenesis.
The completion of all mutational events in any either of two routes leads to malignant 
transformation. There exists competition between these two routes in tumour development. 
We assume that only a fraction f of the tumours developing in wild-type mice have arisen 
by the p53 mediated pathway. It is then only the p53 mediated tumours whose frequency 
is increased in the p53 deficient genotypes.
The non-p53-mediated path has unspecified structure and parameters. However, knock-out 
of p53 gene enhances only the p53-mediated tumour development. In p53+/‘ and p53*/_ mice, 
the great majority of tumours develop by the p53-mediated route. For these reasons, the 
p53-mediated route has been the focus on in our studies, and we will not discuss further 
the non-p53-mediated path.
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7.3 Simulation results
As in Chapter 5, we have simulated 3, 4 and 5 stage models for p53-mediated 
tumorigenesis in p53 wild-type mice with a range of f  values (£=10 or 1%). As discussed 
in Chapter 5, the total incidence of tumorigenesis in wild-type mice is about 10%, and the 
incidence of the p53-mediated tumorigenesis will be about 10% times f. Therefore we have 
in each case chosen the mutation rate to give approximately O.lf times the p53-mediated 
tumour incidence in wild type mice by 600 days. The corresponding p53-mediated tumour 
incidences for p53+/‘ and P53*'" mice then follow by subtracting 1 or 2 stages respectively 
without changing the mutation rate. For presentation, we have computed the number of 
p53-mediated tumours predicted to have appeared by 16 and 80 weeks.
For all models, it has been generally found that the number of tumours predicted in p53+/‘ 
and p53'/_ genotypes decreases as the fraction f decreases (Table 7.1). This relationship is 
strongly dependent on the number of stages required for malignant transformation in p53 
wild type mice.
Table 7.1 shows that 3 and 4-stage models still predict the early development of large 
number of tumours in p53‘A mice even when only 1% of all tumours in wild-type mice 
develop by the p53 mediated route. The model-predicted age-incidence distribution of 
tumours is shown in Figure 7.2 (A and B) and demonstrates much faster tumour 
development predicted by the model for p53_/‘ mice than occurs experimentally. These 
results indicate that f  must be lower than 1% if the predicted number of tumours in p53'/_ 
mice is to be compatible with experimental data. However the predicted number of
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the number of tumours in p53+/' mice is already less than the experimentally observed 
number (Table 7.1). Furthermore, Figure 7.2(D) shows slower tumour development in 
p53+/‘ mice than occurs experimentally. The 3-stage model also predicts the early 
development of large numbers of tumours in p53+/' mice when f=l%. For compatibility 
with experimental data in p53+/' mice, it is required that the mutation rate is between 10'7 
and 10"6/cell division, but, tumour development predicted by the model in p53'/_ mice is 
still faster than occurs experimentally. Therefore, for both the 3 and 4-stage models, it is 
impossible to find a value of f  which makes the predicted number of tumours in both p53 
deficient genotypes consistent with the experimental data.
Table 7.1 Predicted tumour development by the p53-mediated pathway in mice of different 
genotypes on 3, 4 and 5 stage models for p53 mediated tumorigenesis with 10% or 1% of 
all tumours in wild type mice developing by the p53 mediated route and 90% or 99% by 
p53 independent pathways.
Fraction Genotype 3-stage model
Tumours/mouse
(SE)*
4-stage model
Tumours/mouse
(SE)*
5-stage model
Tumours/mouse
(SE)*
16 weeks 80 weeks 16 weeks 80 weeks 16 weeks 80 weeks
10% (Mutation rate=3.8xl0'6) (Mutation rate=2.5xl0'3) (Mutation rate=5xl0'5)
p53+* 0.0003
(0.0003)
0.018
(0.0016)
0.0017
(0.0006)
0.018
(0.002)
0
(0)
0.029
(0.003)
p53+/' 1.8
(0.17)
55.7
(0.89)
0.029
(0.002)
5.3
(0.03)
0.0028
(0.001)
0.2
(0.005)
p53J- 1.7xl04
(79.2)
9.0xl04 
(4.2x102)
1.4xl02
(4.6)
2.4x103 
(15.7)
0.3
(0.02)
46.4
(0.55)
1% (Mutation rate=2xl0'6) (Mutation rate=9xl0'6) (Mutation rate=10'5)
p53+/+ 0
(0)
0.0023
(0.0006)
0.0003
(0.0003)
0.0044
(0.001)
0
(0)
0.0036
(0.001)
p53+/‘ 0.5
(0.08)
15.6
(0.68)
0.0012
(0.0004)
0.3
(0.006)
0.0005
(0.0004)
0.0048
(0.001)
P53-"- 8.9xl03
(41.6)
4.7x104 
(2.2x102)
11.3
(0.34)
3.1xl02
(2.7)
0.0011
(0.0003)
0.36
(0.007)
* SE = standard error of mean number of tumours per mouse
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When f  is less than 10%, the 5-stage model predicts fewer tumours in both p53 deficient 
genotypes (Table 7.1) and the age-incidence also shows slower development of tumours 
(Figure 7.2 (E) and (F)). Therefore we studied the 5-stage model extensively and observed 
compatability with the experimental data only for the 5 stage model with f  = 20% (i.e 20% 
of all tumours in wild type mice developing by the p53 mediated pathway). For f  > 20% 
an excess of tumours are predicted for p53'/_ mice and for f  < 20% a deficit of tumours is 
predicted in the p53+/‘ genotype (figure 7.3). The data for p53-mediated tumours for f  = 0.2 
are shown in table 7.2.
Table 7.2 Predicted tumour development by the p53 mediated pathway in wild type and 
p53 deficient mice on a 5 stage model for p53 mediated tumorigenesis with 20% of all 
tumours in wild type mice developing by the p53 mediated route and 80% by p53 
independent pathways.
Genotype 5-Stage Model
(Mutation rate = 7.5 x 10'5 ) 
p53-mediated tumours /mouse 
(SE)*
16 weeks 80 weeks
p53+/+ 0 0.038
(0) (0.003)
p53+/ 0.006 0.83
(0.001) (0.02)
p53^ 0.863 193
(0.028) (1.5)
* SE = standard error of mean number of tumours per mouse
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Figure 7.2 Predicted age-incidence pattern of p53-dependent tumour development for mice 
of three genotypes for the multipath multistage model with (A) 3-stage model and f=10%,
(B) 3-stage model and f=l%, (C) 4-stage model and f=10%, (D) 4-stage model and f=l%, 
(E) 5-stage model and f=10%, (F) 5-stage model and f=l%. The broken lines in the 
diagrams show the incidence of experimental tumours (data from Donehower et al (1995), 
dashed line).
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Figure 7.3 Predicted age-incidence pattern of p53-dependent tumour development for mice 
of three genotypes for the 5-stage multipath model with (A) 100, (B) 60, (C) 30, (D) 20, 
(E) 10, and (F) 1% of tumours in wild type mice arising by the p53 dependent route. The 
broken lines in the diagrams show the incidence of experimental tumours (data from 
Donehower et al (1995), dashed line).
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7.3 Discussion
We have developed a multipath multistage model invoking a p53 independent pathway 
which exists in parallel with a p53 mediated route of tumorigenesis. Only the latter route 
is enhanced in p53 deficient genotypes. On this type of model, the mutation rates are 
independently fixed and these inherent rates are not changed by p53 inactivation, which 
only alters the number of stages required for malignant transformation by the p53-mediated 
route.
This model is supported by some experimental data. Heavly et al (1993) and Kemp et al 
(1994) have shown that the remaining p53 allele is not lost in all spontaneously-developing 
tumours in p53+/* mice. This means some tumour development in p53+/' mice may not 
involve p53 inactivation. Also, human cancer data has shown that only a proportion of 
developing malignancies involve p53 mutations, and this fraction varies with the type of 
cancer (see Table 1.5.2 in Chapter 1).
The disruption of the p53 gene accelerates p53-mediated tumour development. However, 
the mean number of tumours in p53+/' and p53_/‘ mice depends on the fraction f  of all 
tumours in wild-type mice developing by the p53 mediated route. The present studies show 
that a higher value of f  results in a larger number of tumours in p53+/' and p53_/* mice. 
This relationship is strongly influenced by the number of events required for malignant 
transformation by the p53-mediated route in wild type mice.
The detailed age-incidence kinetics of developing tumours cannot be computed on this
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model since the process of tumour development is only defined mechanistically for the p53 
mediated pathway - the non-p53-mediated path has unspecified structure and parameters. 
For this reason, only the tumours developing by the p53 mediated route are shown; in the 
p53+/' and p53_/‘ (but not wild type) genotypes these will be the great majority of tumours. 
It has been shown that more reasonable tumour numbers may be predicted for each of the 
genotypes by 5-stage p53 mediated pathway with f=20%. This means that the multipath 
multistage model does seem capable of being reconciled with most of the data.
However, reconciliation of the model with the data is only possible with a somewhat 
contrived choice of parameters, and with the p53 independent pathway a 'black box' for 
tumour development which is invoked as a means of reconciling the experimental data with 
model predictions, but does not have any given mechanistic structure of its own. In the 
next chapter, we will consider a class of models which seem able to account for the 
experimental findings in a more natural way.
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Chapter 8
Multigate Model of Tumorigenesis with the p53 Gene 
as a Rate-Modifier of Gate-Pass Events
142
8.1 Introduction
In each of the preceding models discussed in the previous chapters, mutations occurred 
independently and the rate of mutation at any stage was unaffected by mutations having 
already occurred at other stages. However, it is a current hypothesis, termed by Lane 
(1992) the ‘guardian of the genome’ concept, that p53 inactivation results in generally 
increased mutation rates, i.e. wild-type p53 acts to confer genetic stability. We now wish 
to consider how this idea made be incorporated in stochastic modelling and how well the 
model accommodates the data. To do this, it may be useful to distinguish between 
mutations which are directly or indirectly tumorigenic.
Directly tumorigenic mutations, whether these are oncogene activations or inactivations of 
tumour suppressor genes, are ‘enabling’ or obligatory events which must accumulate to a 
minimum number, or possibly to one of several alternative configurations, for malignant 
transformation of the affected cell. We may consider that tumorigenesis requires a number 
of regulatory ‘gates’ to be passed and that a tumorigenic mutation of direct type alters a 
gateway gene and corresponds to a gate-pass event. The gate-pass events are the stages of 
the multistage model. However, we may conceive of a different class of mutations (indirect 
mutations) which are not enabling events in themselves but modifiers of the tumorigenic 
mutation rate. This leads to a multi-gate model of tumorigenesis with mutation rates under 
the control of rate-modifier genes. Mutated rate-modifier genes lead to altered mutation 
rates in gateway genes. A similar concept has been proposed by Loeb (1991), who has 
argued for the existence of a 'mutator phenotype' and by Sherman and Portier (1994), who 
have termed such a process a ‘multi-hit' model to distinguish it from multi-stage. The
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structure of a 3-gate model, associated with a 2-stage modifier (p53 inactivation) pathway 
is depicted in Figure 8.1. A more detailed breakdown of the structure is given in Figure 
8.2. For simplicity, this new model is termed the multi-gate/multi-stage model.
k rate-modifier factor
self-renewal self-renewal•self-renewal
Gate-1
mutantStem cell
p53
wild-type
Gate-2
mutant
Malignant
Cell
Detectable
Tumour
differentiation/death differentiation/death differentiation/death
Figure 8.1 General structure of 3-gate/2-stage model for tumorigenesis.
A feature of the model is that mutation of the gateway genes alone (without modifier gene 
mutations) may lead to malignant transformation, whereas modifier mutations cannot 
achieve transformation without gate-pass events. Therefore, only a proportion of tumours 
developing by this gateway will be associated with modifier mutations. This proportion 
will depend on the numbers of genes involved in the gateway and in the modifier pathway, 
and on rates of mutation of modifier genes and of gateway genes, when modifier mutations 
have or have not occurred. Generally, the proportion of modifier-associated mutations will 
be low unless there are more gates than modifier stages or unless the modifier genes are
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themselves more prone to mutation than the gateway genes. We now wish to establish 
whether this type of model can account for tumour incidence data in p53 deficient mice.
To apply these concepts to tumorigenesis in p53 deficient mice, we propose that p53 is a 
rate-modifier gene whose inactivation requires 2-stages in wild-type mice and 1-stage 
inactivation in p53 null heterozygous (p53+/') mice. Of course the gene is already 
inactivated in p53 null homozygous (p53'/_) mice. In each genotype, the same number of 
gateway gene mutations is required. Gateway genes have a baseline mutation rate p when 
p53 function is maintained, which is increased to mutation rate kp when p53 function is 
lost. The parameter k will be termed the rate modifier factor. The mutation rate for two 
stage loss of p53 function is assigned the independent value X. Computer simulations have 
been carried out for a range of values of the number of gates in the model, for a range 
of values of the mutation rates of the modifier genes and (independently) the mutation rates 
of the gate-pass genes, and a range of values of the modifying factor (the scaling factor 
for gate-pass mutation rate).
In this chapter, we intend to provide a quantitative approach to the understanding of the 
importance of rate-modifier genes in the onset of malignant tumours. Firstly, we will 
consider some quite general questions. It is intended to explore how the rate-modifier 
factor and the number of stages for the rate modifier process, the mutation rate of the rate- 
modified genes and the gate-pass genes, as well as the number of gates required for 
malignant transformation, affect tumorigenesis. How many tumours will arise by the gate- 
pass mutations only compared with the gate-pass plus modifier mutations? How does the 
proportion of tumours arising by the gate-pass plus modifier mutations change with age? 
After consideration of these generic questions, the model will be applied to p53 mediated 
tumorigenesis.
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8.2 Three-gate/two-stage model of tumorigenesis
The detailed structure, expanded from Figure 8.1, of three-gate/two-stage model of 
tumorigenesis is represented in Figure 8.2. This expansion is necessary for mathematical 
development (see appendix 2). The essential features of this model are:
(1) Cells in each state (excluding the malignant state) are presumed to follow the Gomp-ex 
stochastic growth process described in Section 3.3 of Chapter 3. The malignant cells are 
assumed to follow linear birth-death stochastic growth.
(2) At each cell division, each daughter cell has a probability of experiencing any one 
mutation (either the gate-pass mutation or the modifier mutation). We do not consider the 
unlikely possibility that both mutations occur simultaneously in the same cell.
(3) The birth-death processes and the mutation processes are independent of one another 
and each cell goes through the above processes independently of other cells.
(4) We assume that the cell cycle time of the stem cells and mutants remains same and is 
not influenced by the mutational events.
Technically, these assumptions imply that the mathematical model portrays the process of 
tumorigenesis as a Markov process. A Markov process describes the fate of any cell at 
time t as depending only on the present state of the cell at time t and not on the past 
history of that cell.
The other multigate/multistage models have the same structure as the three-gate/two-stage 
model. These models differ only in the number of gates for malignant transformation 
and/or number of stages for rate-modifier process.
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8.3 Simulation studies and results
The behaviour of a set of cells is followed using discrete event simulations (Maisel and 
Gnugnoli, 1972) in which the evolution of the population of cells is updated at each cell 
division. The simulation process has similar structure to that described in Section 3.4 of 
Chapter 3 (see appendix 3). It differs only in having the new possibility of rate-modifier 
mutations.
In our simulation studies, we have considered k-gate/2-stage and k-gate/1-stage (k=2, 3, 
or 4) models. The baseline parameter values have been chosen to be representative of cell 
kinetics in the developing mouse. The values used for the simulations refer to the section 
3.4 of Chapter 3. At time zero, corresponding to fertilization, only a single normal stem 
cell (fertilized ovum) is present. 104 simulations were carried for each choice of the 
parameters in the models. Each simulation is terminated when the age of mouse reaches 
600 days. The number of detectable tumours and the times of the first ten tumours are 
recorded. A tumour is considered to be detectable when its size reaches 106 cells.
The relative risk, is defined as the ratio of cumulative tumour incidence rate (by 600 days) 
with and without the rate-modifier process. The proportion of tumours which arise by gate- 
pass mutations only are used to evaluate the importance of the rate-modifier mutations in 
the onset of malignant tumours.
8.3.1 Kinetics of appearance of tumours
Figure 8.3 shows the predicted kinetics of appearance of tumours in mice using this new
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model. It is found that no matter how many gates are required for malignant 
transformation, the existence of the rate-modifier process means that tumour incidence is 
always increased relative to the same process in the absence of the rate-modification. 
However the magnitude of any such difference strongly depends on the rate-modifier 
factor, the number of stages and gates, and the mutation rate of gate-pass and modifier 
events. For example, with a two-stage rate-modifier process and lower gate-pass mutation 
rate, the difference is negligible when the rate-modifier factor is 5 or less (Figure 8.3).
Considering tumours which arise by gate-pass mutations only compared with the gate-pass 
plus modifier mutations, it is very interestingly found that tumours arising by gate-pass 
mutations only occur slightly earlier than those by the gate-pass plus modifier mutations 
although this difference is influenced by the number of gates and stages, the rate-modifier 
factor, and the mutation rate for gate-pass and modifier events (Figure 8.4).
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(Figure 8.3 to be continued)
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Figure 8.3 The kinetics of appearance of tumours in mice under the multigate model with 
rate-modifier process. The graphs are labelled by the value of rate-modifier factor k. (A) 
2-gate/l or 2-stage model with gate-pass mutation rate 3x10'7 and modifier mutation rate 
10'4; (B) 3-gate/1 or 2-stage model with gate-pass mutation rate 10'5 and modifier mutation 
rate 10*4; (C) 4-gate/l or 2-stage model with gate-pass mutation rate 5x1 O'5 and modifier 
mutation rate 1CT4.
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Figure 8.4 Comparison of latent period distributions of tumours arising by gate-pass 
mutations only with tumours arising by gate-pass plus modifier mutations. In each 
block, the upper lane shows the time of appearance of tumours arising by gate-pass 
mutations only, and the lower lane shows the time of appearance of tumours arising by 
gate-pass and modifier mutations. The value of the modifier factor k is labelled in each 
block. (A) 2-gate/l-stage model with gate-pass mutation rate 3x1 O'7and modifier 
mutation rate lO-6; (B) 2-gate/l-stage model with gate-pass mutation rate 3x1 O'7and 
modifier mutation rate 10"4; (C) 3-gate/l-stage model with gate-pass mutation rate 10"5 
and modifier mutation rate 10"5; (D) 3-gate/l-stage model with gate-pass mutation rate 
10"5 and modifier mutation rate 104  (E) 4-gate/1-stage model with gate-pass mutation 
rate 5x10"5 and modifier mutation rate 5x1 O'5; (F) 4-gate/l-stage model with gate-pass 
mutation rate 5x10"5 and modifier mutation rate 104; (G) 2-gate/2-stage model with 
gate-pass mutation rate 3x1 O'7 and modifier mutation rate 10*4; (H) 3-gate/2-stage 
model with gate-pass m utation rate 10'5 and modifier mutation rate 10-4, (I) 
4-gate/2-stage model with gate-pass mutation rate 5x10"5 and modifier mutation rate
10-4.
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8.3.2 Relative risk
For all models, the relative risk (ratio of accumulated tumour incidences in presence and 
absence of the rate-modifier process) increases with the rate-modifier factor (Figure 8.5). 
However, the steepness of this relationship is strongly dependent on the mutation rate of 
the gate-pass and modifier events, and the number of stages and gates (Figure 8.5). With 
fewer stages, and/or higher rate of modifier mutations, the relative risk changes rapidly 
with the rate-modifier factor (Figure 8.5). Surprisingly, for 2-gate/2-stage and 3-gate/2- 
stage models, when the modifier mutation rate is lower, even if the rate-modifier factor 
reaches 100, the relative risk are only 1.11 and 1.09, respectively.
8.3.3 Proportion of tumours arising by gate-pass mutations only
The proportion of tumours which arise by gate-pass mutations only reduces with increasing 
rate-modifier factor (Figure 8.6). However the details of this relationship are strongly 
dependent on the number of stages and gates, as well as the rate of the gate-pass and 
modifier mutations. Surprisingly, for the two-gate/two-stage model, even if the rate- 
modifier factor is high as 100, nearly all tumours still arise by gate-pass mutations only 
when the rate of modifier mutations is close to the rate of gate-pass mutations (see left part 
of Figure 8.6 (D)).
Very interestingly, the proportion of tumours arising by gate-pass mutations plus rate- 
modified gene mutation increases with age, implying that tumours with modifier mutations 
will be relatively over-represented amongst late-occurring tumours. However, this 
relationship is influenced by the rate-modifier factor, the number of stages and gates, and 
the rate of the gate-pass and modifier mutations (Figure 8.7).
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8.3.4 Tumour multiplicity
The mean number of tumours per mouse increases with the rate-modifier factor (Figure 
8.8). However, this relationship is influenced by the number of gates and stages and the 
mutation rate of the rate-modifier genes and the gate-pass genes (Figure 8.8).
8.4 Application to tumorigenesis in p53 deficient mice
To apply these new models to tumorigenesis in p53 deficient mice, we propose that p53 
is a rate-modifier gene whose inactivation requires 2-stages in wild-type mice and 1-stage 
inactivation in p53+/' mice; of course the gene is already inactivated in p53'7' mice. In each 
genotype, the same number of gateway gene mutations is required. Gateway genes have 
a baseline mutation rate p when p53 function is maintained, which is increased to mutation 
rate kp when p53 function is lost. We have considered 2-gate, 3-gate and 4-gate models 
and have in each case chosen the mutation rate X and p, and rate-modifier factor k to 
match tumour incidence observed experimentally (Donehower et al, 1995) in wild type 
mice. However, with smaller value of the rate-modifier factor (k < 25), it was found that 
the tumour incidence in wild type mice does not change very much, so we have to assign 
the value of rate-modifier factor k by choosing k to match tumour incidence observed 
experimentally in p53+/‘ mice without changing the mutation rate. The corresponding 
tumour incidence for p53'7' mice then follows without changing the rate-modifier factor and 
mutation rate. For presentation, we have computed the number of tumours predicted to 
have appeared by 16 and 80 weeks, close to the observed median latency in p53'7' and 
p53+/' mice, in each of these situations.
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We have observed that better agreement with the experimental data is found when the 
mutation rate of the second p53 allele (second stage of modifier process) is higher than that 
of the gate-pass genes (Table 8.1). In support of this hypothesis, some evidence suggests 
that following loss of the first p53 allele, loss of the second allele occurs more easily 
(Harvey et al., 1993). Further experiments will be needed to confirm this possibility.
Interestingly, when we choose the appropriate value of parameters in the model, both two- 
gate and three-gate models can be compatible with the experimental data. However, it 
seems very difficult to find appropriate values of parameters in the 4-gate model to 
reconcile with the experimental data. Table 8.1 and figure 8.9 show predicted tumour 
incidence data for the three mouse genotypes by two-gate and three-gate model.
Table 8.1 Predicted tumour development in wild type and p53 deficient mice on 2-gate 
and 3-gate models with 2 stage modifier (p53 inactivation) pathway.
Genotype 2-gate model with 2-stage modifier 3-gate model with 2-stage modifier
(P]=g2=3.7xl0'7; X,j=3.7xl0‘7; (m.1=h2=h3=1 0*5; X,j=10'5;
Xa=5xl0'4; k=10) }J2=1.5xl(r';k=10)
Tumours/mouse Proportion of 
tumours 
developing by 
80 weeks with 
inactivated p53 
(%)
Tumours/mouse Proportion of 
tumours 
developing by 
80 weeks with 
inactivated p53 
(%)
16 weeks 80 weeks 16 weeks 80 weeks
p53(+/+) 0.003 0.14 0.1 0.0008 0.10 0.6
p53(+/-) 0.009 0.88 84.0 0.0021 1.29 89.4
P53(-/-) 0.95 33.91 100 0.56 375 100
Notice that the mean number of tumours/mouse is now near 1 for p53+/* and p53'/_ mice by 
80 and 16 weeks respectively, although large tumour numbers would still be predicted for 
p53‘;' mice by 80 weeks on 3-gate model; however, in practice no such mice will survive 
to this time.
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Figure 8.9 Predicted age-incidence pattern of tumour development for mice of three 
genotypes for the multi-gate model with 2 modifier stages. (A) 2-gate model with Mi= M2 
= 3.7xl0 '7 , Xi = 3.7xl0'7, 5x10^ , k = 10; (B) 3-gate model with Mi =m2 = M3
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incidence of experimental tumours (data from Donehower et al, 1995)
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The model provides prediction of the proportions of tumours which occur in each genotype 
in association with p53 inactivation; these are shown for tumours accumulated by 80 weeks 
in table 8.1. We have also computed the proportion of p53 inactivation associated tumours 
as a function of mouse age in the wild-type and p53+/' genotypes and have observed that 
this proportion shows a tendency to increase with age (Figure 8.10), implying that p53 
inactivated tumours will be relatively over-represented amongst late-occurring tumours.
8.5 Discussion
A new mathematical model has been developed for multistage tumorigenesis. Under this 
new model, tumorigenesis is viewed as passing several genetic gates with multistage rate- 
modifier of gate-pass events. The experimental evidence in support of this new model is 
found in the work of Holliday (1989) and Hartwell and Weinert (1991). Hartwell and 
Weinert pointed out that it is highly improbable that six successive spontaneous changes 
(as seems to be required on the multistage model for some tumours) could occur within 
a clone of cells in the mammalian organism to produce a tumour even after decades of 
selection when the spontaneous mutation rate is less than 10'5 mutation/gene/generation. 
One way out of this dilemma would be if the cell destined to produce the tumour acquired 
an increased mutation rate early in its history. As shown in chapter 3, the tumours only 
occur in very small numbers of mice even if only three changes are required when the 
spontaneous mutation rate is less than 10'5 mutation/gene/generation. Although the 
application of the multigate model theory has been principally to tumorigenesis in p53 
deficient mice, it is possible that other rate-modifying pathways exist. For example,
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Dietrich et al (1993) have recently reported that Mom-1 is a major modifier locus affecting 
Min-induced intestinal neoplasia in the mouse.
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Figure 8.10 Relationship between the proportion of p53 inactivation associated tumours 
and mouse age in the p53+/' genotypes. It is difficult to describe this relationship in the p53 
wild type due to very low proportion of p53 inactivation associated tumours by 80 weeks.
The importance of the rate-modifier process in tumorigenesis strongly depends on the 
number of stages and the mutation rate for the rate-modifier process, rate-modifier factor, 
and the number of gates required for malignant transformation. There are some possible
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mechanisms which may increase the importance of the modifier pathway: (1) the modifier 
mutation rates may be much higher than the gate-pass mutation rates; (2) the number of 
stages for rate-modifier process may be much less than the number of gates; (3) the rate- 
modifier factor may be high, or any combination of these above. Otherwise, the rate- 
modifier process will not demonstrate any advantage. As shown, when the mutation rate 
of the gate-pass and modifier events is similar, analysis of the two-gate/two-stage model 
shows that almost all tumours arise by gate-pass mutation only even when the rate-modifier 
factor reaches 100.
The multigate model differs from the multistage/multipath model described in the previous 
chapter in postulating that p53 inactivation has a rate-modifying role in a tumorigenesis 
pathway which can nevertheless proceed independently of p53. An illustration of this 
possibility may be helpful. Here, consider a tumorigenic process in which the tumour 
suppressor gene Rb also plays a role. Suppose for example that inactivation of both Rb 
alleles are two enabling (gate-pass) genetic events in a particular tumour type. Then we 
expect that some tumours will be Rb doubly mutant (with intact p53) others will be Rb 
doubly mutant with inactivated p53. However, according to the multigate/multistage model, 
no tumours will be found to have suffered only p53 inactivation. The inactivation of p53 
would therefore appear to be 'optional' in this mechanism of tumorigenesis. By contrast the 
multistage multipath model requires that if p53 is implicated in a tumorigenic pathway then 
any alternative pathway not involving p53 will instead have to involve some other genetic 
events (eg some genetic event additional to, or as an alternative, to the Rb inactivation 
considered in the example) ie p53 inactivation fulfils a role which is not 'optional' and 
would have to be replaced if not present. It is also a feature of the multigate model that 
p53 inactivation should precede at least one of the gate-pass events, whereas on the 
multistage model, p53 inactivation could just as easily come last.
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We only analyse tumours in p53 deficient mice where p53 acts principally as a tumour 
suppressor gene. The case where p53 mutation acts to produce a dominant oncogene is not 
of major importance in these mouse genotypes and is not considered. Of course, it must 
be appreciated that such mutations do occur in human tumours, and that p53 mediated 
tumorigenesis will be more complex than discussed here.
Of course, the main difference between the models is that the multigate model is 
essentially a genetic instability model and requires that p53 inactivation be a destabilising 
event. Experimental evidence on this is not wholly consistent at present, with some 
workers reporting a significant increase in the mutation rate at a particular locus (Xia et 
al, 1995; Havre et al, 1995) and no difference being reported at other loci (Sands et al, 
1995). Also, it is possible that the tumorigenic events which are enhanced by p53 
inactivation correspond to chromosome abnormalities (Bouffler et al, 1995) or gene 
amplification (Livingstone et al, 1992; Yin et al, 1992) or other heritable events rather than 
traditional point mutations; also it is possible that the influence of p53 inactivation is 
confined to a restricted set of genes rather than being across the genome. It is also possible 
that the main impact of p53 inactivation will be in relation to the processing of DNA 
damage and that its role will be seen more clearly when mice of differing genotypes are 
subjected to graded doses of DNA-damaging agents. However, as we have emphasized at 
several points, the present model does not distinguish between increased production of 
genomic lesions in each cell and increased survival probability of lesion-bearing mutants. 
Bodmer and Thomlinson (1996) have recently argued for increased mutant survival, rather 
than increased production of primary genomic lesions, as the mechanism by which p53 
inactivation leads to deteriorating genetic uniformity of a clonal cell population. The 
present model is compatible with this interpretation.
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Chapter 9
Effect of Growth Patterns of Stem Cells on Tumour 
Spectrum and Multiplicity
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9.1 Introduction
In previous chapters we have considered the development of tumours without 
distinguishing between the different tissue in which tumours may develop develop. We 
shall now see what happens when there are two or more distinct tissues. It is well known 
that the kinetics of growth of a tissue can strongly influence the age-specific incidence 
curve of cancer of this tissue type. Moolgavkar and his colleagues (1981 and 1986) have 
shown that the patterns of cancer incidence rate in human populations are explicable by 
the growth patterns of human tissues.
Recently, in the study of tumorigenesis in p5 3-deficient mice, differences in tumour spectra 
(i.e. tumours of differing pathological type) between the p53-deficient heterozygotes and 
homozygotes have been reported (Table 9.1; Donehower et al., 1995). These authors 
proposed as an explanatory hypothesis for the observed differences is that there are 
different temporal "windows of opportunity" for cancer development in different tissue 
compartments. It was thought that the greatest rates of cell division, cell numbers, and 
programmed genetic rearrangements may be in the lymphoid compartments during the 
neonatal stages. In the absence of wild-type p53, the large numbers of rapidly dividing 
cells in these lymphoid compartments may be more likely to incur further oncogenic 
lesions and progress to an early cancer. The presence of a single p53 allele in the p53 
heterozygous mice may greatly reduce the likelihood of these lymphoid target cells' 
developing the requisite secondary oncogenic lessons, particularly after thymic involution, 
and this would open up "windows of cancer opportunity" in other tissue compartments.
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To verify their hypothesis, the competition of tumour development in two different growth 
patterns of mouse tissues has been introduced into the tumorigenesis model, i.e. multistage 
models and multigate/multistage models. The computer simulation studies are used to show 
the proportion of the first-appearing tumours arising from two different tissues and tumour 
multiplicities in these tissues. It is intended to explore how the host factors, such as the 
spontaneous mutation rates and the number of stages, affect this proportion and tumour 
multiplicities.
Table 9.1 Tumour spectrum in C57BL/6 x 129/Sv p53 deficient mice (Donehower et al, 
1995)
p53'/_ p53+/"
65% lymphomas 36% osteosarcomas
21% hemangiosarcomas 28% lymphomas
4% testicular tumours 9% hemangiosarcomas
4% undifferentiated sarcomas 7% rhabdomyosarcomas
2% osteosarcomas 4% fibrosarcomas
1% mammary adenocarcinoma 2% undifferentiated sarcomas
1% medulloblastoma 2% malignant schwannomas
1% malignant schwannomas 1% leiomyosarcoma
1% glioblastoma 1% myxosarcoma 
1% lung adenocarcinoma 
1% mammary adenocarcinoma 
1% squamous-cell carcinoma 
1% intestinal carcinoma 
1% salivary-gland myeloepithelioma 
1% harderian-gland carcinoma 
1% pituitary-gland adenoma 
1% preputial-gland carcinoma
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9.2 Multistage models
Firstly, tumorigenesis is interpreted using the multistage model, in which there exists 
competition of tumour development in two mouse tissues with different growth patterns 
(Figure 9.1). For the sake of simplicity, we consider two tissues which differ only in the 
parameters describing cellular growth and death rates, i.e., with the same mutation rate and 
the same number of mutational events required for malignant transformation. In tissue I, 
the stem cells follow the Gomp-ex growth model described in Section 3.3 of Chapter 3. 
In tissue n , stem cells follow a Gamma growth model, which is described by the piecewise 
continuous equation
for initial growth from single cell, where N(t) is the expected number of cell population 
in tissue II, and Cj and c2 are net growth rate, the growth pattern for tissue II corresponds 
to a stem cell population which peaks in early post-natal life and slowly declines thereafter. 
Such a pattern might be applicable to some classes of hemopoietic cells and to cell 
populations like retinoblasts which disappear in adult life. In our studies, for tissue I, the 
values of the parameters are those given in Chapter 3. For tissue II, c^O.9211/day, 
c2=0.0065/day, and the death rate is 0.085/day. The expected growth curve of both tissues 
is shown in Figure 9.2.
f
e 20*lg (^MO)
t<20 days 
20</<40 days 
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Figure 9.1 Multistage model of tumorigenesis with competition of tumour development 
in two different murine tissues.
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To explore the effect of the growth pattern of stem cells on the tumour spectra and 
multiplicity, computer simulation is used. The simulation process is quite similar to that 
described in Chapter 3, the only difference being that there are two tissues in this 
simulation. The simulation is terminated when the age of mouse reaches 600 days. The 
number of tumours in each tissues and the time of first ten tumours are recorded. For each 
set of parameters in the model, 104 simulations are repeated.
In our simulation studies, we suppose the growth and death rate of mutants are same as 
that of stem cells from which the mutants arose and the mutation rate at each stage are 
same.
9.2.1 Time of the first tumour appearance
For all models, the type II tumours occur earlier than type I tumours (Figure 9.3), implying 
that earlier developing tissues (i.e., tissues having the greatest rates of cell division and 
greater number of cells occurring at earlier age), give rise to earlier appearance of tumours. 
This difference is influenced by the spontaneous mutation rate and the number of 
mutational events required for malignant transformation. With higher mutation rate and 
fewer number of stages, the difference is not marked (Figure 9.3).
9.2.2 Spectra of first-appearing tumours
For one-stage tumorigenesis, most of the first-appearing tumour are type II (Figure 9.4
(A)), whereas, for four-stage tumorigenesis, most are type I (Figure 9.4 (D)). However, for 
two- and three-stage tumorigenesis, with higher mutation rate, most are type II, but with 
lower mutation rate, most are type I (Figure 9.4 (B) and (C)).
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Figure 9.4 also shows that the proportion of type II tumours in the first-appearing tumours 
decreases with increasing number of stages required for malignant transformation and with 
decreasing spontaneous mutation rates (The one-stage model is anomalous; this is due to 
a 'cross-over' between the Gomp-ex and Gamma growth curves at early times).
We have also computed the proportion of type II tumours as a function of mouse age and 
have observed that this proportion tends to decrease with age (Figure 9.5), implying that 
type II tumours will be relatively over-represented amongst early-occurring tumours 
whereas type I tumours will be relatively over-represented amongst late-occurring tumours. 
However, this relationship is influenced by the spontaneous mutation rate and the number 
of mutational events. With smaller number of mutational events and higher value of the 
spontaneous mutation rate, this relationship tends to flatten out.
9.2.3 Multiplicity analysis of type I and II tumours
Interestingly, for all models, by 120 days, the mean number of type EE tumours per mouse 
is greater than type I, however, by 600 days, the mean number of type II tumours is less 
than type I (Table 9.2). This indicates, in tissue II, most tumours appear in younger ages, 
whereas in tissue I, most tumours appear in older age group. Unfortunately, in the 
experiments, such a result may not be observable because the first tumour may cause 
mouse death (or humane sacrifice).
Table 9.2 also shows that the mean number of both types of tumours decreases with 
decrease in the spontaneous mutation rates, and with increase in the number of stages 
required for malignant transformation. This is consistent with the previous observations.
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Table 9.2 Mean number of tumours per mouse predicted by the multistage model
Number of stages Spontaneous 
mutation rate
Mean number of 
type I tumours
Mean number of 
type II tumours
120 days 600 days 120 days 600 days
1 io-4 6.95x10“ 2.35x10s 3.74xl05 9.91x10s
io-5 6.98xl03 2.44x105 3.77x10“ 1.00x10s
IO'6 6.96xl02 2.42x10“ 3.77xl03 9.96xl03
IO'7 6.97x10' 2.38xl03 3.79xl02 9.97x102
10‘8 6.95x10° 2.41xl02 3.78x10' 9.93x10'
IO'9 6.80x10-' 2.37x10* 3.72x10° 9.91x10°
2 10'“ 2.77xl02 3.74x10“ l.OlxlO3 3.95xl03
IO'5 3.06x10° 3.67xl02 9.53x10° 3.65x10'
IO'6 3.40x10'2 3.63x10° 1.14x10-' 3.60x10-'
IO'7 0 2.80xl0"2 4.00x10“ 4.00x10-“
3 10-4 5.57x10-' 3.75xl02 1.20x10° 7.78x10°
5xl0'5 6.10x1 O'2 4.64x10' 1.79x10-' 1.02x10°
IO'5 5.00x10-“ 3.63x10-' 3.40xl0"3 6.70xl0"3
4 IO’4 5.00x10-“ 2.49x10° l.OOxlO'3 l.OOxlO"2
5x1 O'5 0 1.50x10-' 0 4.00x10-“
10J 0 2.00x1 O'3 0 0
9.3 Multigate/multistage models
We now consider the multigate/multistage model to provide interpretation of tissue-specific 
competitive tumorigenesis (Figure 9.6). The assumptions regarding the two tissues are as 
before. Computer simulations have been carried out for a range of values of the number
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of gates in the model, for a range of values of the mutation rates of the modifier genes and 
(independently) the mutation rate of the gate-pass genes, and a range of values of the 
modifier factor.
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Figure 9.6 Multigate/multistage model of tumorigenesis with competition of tumour 
development in two different tissues.
9.3.1 Time of the first tum our appearing
It is very interestingly found that type II tumours still occur earlier than type I tumours 
under the multigate/multistage model although this difference is influenced by the rates of 
the gate-pass and modifier mutation, number of gates, and modifier factor (Figure 9.7).
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9.3.2 Proportion of type II tumours as a function of the modifier factor
Surprisingly, the relationship between the proportion of type II tumours and the modifier 
factor seems to follow no simple rules for the multigate model with 2-stage rate-modifier 
process (Figure 9.8 (Bl), (B2) and (B3)). However, for the multigate model with 1-stage 
rate-modifier process, this proportion decreases with the modifier factor down to a 
minimum, with an increase following that minimum (Figure 9.8 (Al), (A2) and (A3)). This 
relationship is influenced by the rate of the gate-pass and modifier mutations, and the 
number of gates (Figure 9.8).
9.4 Proportions of type I and II tumours in p53 deficient mice
Tumorigenesis in p53 deficient mice can be interpreted by the multistage multipath model 
or by the multigate/multistage model as described in the two previous chapters. As shown 
above, the proportion of type I and II tumours in p53+/* and P53'7' can be predicted by the 
multigate/multistage model. Table 9.2 shows how this proportion changes with age. By 120 
days, in both genotypes, the proportion of type II tumours is higher than that of type I, 
however, by 300 or 600 days, in p53+/', the proportion of type II tumours is lower, 
whereas, in p53'/_, the proportion of type II tumours is still higher.
With the multistage multi-path model, because an unknown route for tumour development 
exists, it seems difficult to predict the proportion of type I and II tumours.
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Figure 9.7 Comparison of time of appearance of tumours in two tissues. In each 
block, the upper lane shows the time of type I tumours appearing, and the lower lane 
shows the time of type II tumours appearing. (A) 2-gate/l-stage model with gate-pass 
mutation rate 3x10 "7and modifier mutation rate 10*6; (B) 2-gate/l-stage model with 
gate-pass mutation rate 3x10‘7 and modifier mutation rate 10-4; (C) 3-gate/l-stage 
model with gate-pass mutation rate 10 '5 and modifier mutation rate 10"s, (D) 
3-gate/l-stage model with gate-pass mutation rate lCF5and modifier mutation rate 10-4;
(E) 4-gate/1-stage model with gate-pass mutation rate 5x1 O'5 and modifier mutation 
rate 10'4.
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Table 9.3 Proportion of type I and II tumours in p53 deficient mice as predicted by 
multigate/multistage model
p53+/ p53J-
Number 
of gates
Tumour
type
Proportion (%) Proportion (%)
120 days 300 days 600 days 120 days 300 days 600 days
2 I 30.6 66.1 86.4 17.0 29.5 29.0
n 69.0 33.7 13.3 69.1 65.0 65.1
i+n 0.4 0.2 0.3 14.1 5.5 5.9
total
incidence 2.3 15.3 56.3 65.1 98.6 100
3 I 35.7 89.7 97.2 31.7 41.0 43.6
n 64.3 10.3 2.6 63.3 51.3 54.1
i+n 0 0 0.2 5.1 7.7 2.3
total
incidence 0.42 7.2 59.3 62.7 99.9 100
9.5 Discussion
Competition of tumour development in two mouse tissues showing different growth pattern 
has been studied by using multistage and multigate/multistage models. As result of this 
competition, the tumour spectra will be different in the different genotypes. However, the 
effect of tissue growth pattern on tumour spectra clearly depends on host factors, such as 
the mutation rate, the number of mutational events required for malignant transformation, 
etc.
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Both multistage and multigate/multistage models demonstrate that tumours occur at 
younger age in the tissues that show a sudden burst of growth in early life. Physically, this 
may be because the earlier great rate of cell division results in the earlier accumulation of 
mutations for malignant transformation.
On the multistage tumorigenesis models, our studies have shown the "windows of 
opportunity" for cancer development in different tissue compartments. With fewer stages 
and higher mutation rate, most first-appearing tumours will arise from the tissue in which 
the greatest rates of cell division occur at an earlier age.
Biologically, the growth of osteocytes (giving rise to bone sarcomas) can be reasonably 
well represented by the Gomp-ex growth curve, whereas growth of lymphoid tissue (giving 
rise to malignant lymphomas) can be presented by a gamma growth curve. Thus, the 
difference in tumour spectra between p53+/‘ and p53';' mice can be shown by the 
multigate/multistage model. Although, we have here supposed that the number of gates 
(i.e., mutational events) required for malignant transformation in two tissues and baseline 
mutation rate in each gate are same, this findings may be still not difficult to rationalize 
with Donehower's hypothesis, i.e. the existence of 'windows of opportunity' for tumour 
development.
In fact, in different tissues, the number of mutational events may be different (Renan, 
1993). Further, the mutation rates for different mutational events (different genes) may be 
also different. As shown in Chapter 3, the number of mutational events and the mutation 
rates determine the time of tumour appearance. At present the exact number of mutations 
required for malignant transformation and the rate of mutations occurring in each tissue 
remain unknown.
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Chapter 10
Experimental Studies on an I n  V i v o  Model System to 
Determine the Effect of p53 Deficiency on 
Cellular Mutation Frequency
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10.1 Introduction
This chapter describes an experimental approach to a central problem of p53-mediated 
tumorigenesis: how to measure the effect of p53 inactivation on mutation frequencies at 
other genetic loci. It is known that the p53 gene is mutated or inactivated at a high 
frequency in a wide variety of human cancers (Nigro et al., 1989; Harris and Hollstein, 
1993). The physiological functions of the p53 protein are not fully understood, but one 
well-known hypothesis states that p53 acts as the 'guardian of genome', i.e., it is a key 
component of a system activated by DNA damage that either arrests the cell cycle in G1 
to allow DNA repair, or initiates apoptosis if the damage is severe (Lane, 1992; 
Donehower, 1994; other references cited in Chapter 1). This is of course consistent with 
the 'modifier' role for p53 suggested in the multigate/multistage model (Chapter 8).
If the 'guardian of the genome' hypothesis is correct, lack of normal p53 function should 
increase the mutation rate elsewhere in the genome. In support of this, some workers have 
reported a significant increase in the mutation rate at particular loci (Havre et al, 1995; Xia 
et al, 1995; Yuan et al, 1995), increase of chromosome abnormalities (Harvey et al, 1993; 
Bouffler et al, 1995), or of gene amplification (Livingstone et al, 1992; Yin et al, 1992). 
However, these data are all demonstrated using in vitro systems. In order to investigate this 
question in vivo, two groups (Nishino et al, 1995; Sands et al, 1995) have used a 
transgenic mouse system (Big Blue) to examine the effect of the presence or absence of 
the functional p53 gene on the rate and pattern of background somatic mutation of the LacI 
transgene in vivo. Surprisingly, no difference in the frequencies of L a d  point mutations 
between p53 wild-type and p53 nullizygous mice was found by both groups.
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One limitation of Big Blue transgenic mouse mutation detection system, which uses 
chromosomally integrated bacteriophage lambda shuttle vectors containing the LacI gene 
as a target for mutagenesis (Kohler et al, 1991; Mirsalis et al, 1994), is that deletions larger 
than 5 kb or insertions larger than 8 kb package inefficiently because of the size of 
constraint on genomic DNA that could be packaged into phage particles. To improve this, 
we have used an alternative transgenic mouse model (ROSA) in which the transgene, LacZ, 
is expressed ubiquitously. By crossbreeding with p53 knock-out mice according to classic 
mouse genetics, we should be able to obtain a LacZ transgenic mouse having heterozygous 
or homozygous p53 null background. LacZ gene mutations can be detected by X-gal 
staining. In an organ section, cells which express functional LacZ gene product, P- 
galactosidase, will stain blue in colour. Therefore, any mutation affecting the enzymic 
activity of P-galactosidase will turn the cells from blue to white. We set out to measure 
the spontaneous and radiation-induced mutation frequencies of LacZ gene in different 
organs, such as skin, liver, spleen, intestine, brain etc.
10.2 Materials and methods
10.2.1 Animals
LacZ transgenic mice (ROSA mice) which were derived by electroporating C57BL/6J ES 
cells with ROSAP-geo trap carrying a reporter gene LacZ were obtained from Friedrich 
and Soriano (1991), and mice lacking one or both alleles of p53 which were derived by 
gene targeting of 129/Sv ES cells were obtained from Donehower et al (1992).
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10.2.2 Genotyping
Genotypes were determined by PCR for the p53 gene. Separate primer pairs were used for 
PCR genotyping each p53 allele.
Primers for the wild type p53 allele were as follows:
WT1: 5' GTG TTT CAT TAG TTC CCC ACC TTG AC 3'
WT2: 5' CTG TCT TCC AGA TAC TCG GGA TAC 3’
Primers for the null p53 allele were as follows:
Ml: 5’ GGG ACA GCC AAG TCT GTT ATG TGC 3’
M2: 5' TTT ACG GAG CCC TGG CGC TCG ATG 3'
The PCR reactions for each allele were performed separately and then mixed before 
running on an agarose gel. The PCR reaction for both the wild-type and null alleles were 
performed using the following standard conditions: 2 pi of sample, 1.5 mM MgCl2, 0.2 
mM dNTP's, 0.2 pM of each primer oligonucleotide (see above), and 0.02 u/pl Taq 
polymerase (Perkin-Elmer) in a 50 pi reaction volume. A total of 35 cycles were used after 
originally denaturing at 94°C for two minutes. In each cycle of the first 34 cycles, the 
protocol was as follows:
30 seconds denaturing at 91°C 
30 seconds annealing at 55°C 
30 seconds elongation at 72°C,
followed by one cycle of 30 seconds denaturing at 91 °C, 30 seconds annealing at 55°C and
four minutes elongation at 72°C.
X-gal staining of the mouse ear punch was used to determine the mouse genotype for LacZ 
(see section 10.2.4).
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10.2.3 Preparation of genomic DNA from mouse tail
Genomic DNA was extracted from the mouse tail according to a standard protocol (Laird 
et al, 1991). Mice were humanely sacrificed before tails were cut, minced in small pieces 
and placed in a microfuge tube containing 0.5 ml lysis buffer (100 mM Tris.HCl pH8.5, 
5mM EDTA, 0.2% SDS, 200 mM NaCl). Proteinase K was added at a final concentration 
of 100 jig/ml and incubated at 55°C overnight. Following complete lysis, the tubes were 
vortexed. Tubes were then spun in a centrifuge for 10 minutes. The supernatant was then 
poured into prelabeled tubes, each containing 0.5 ml of isopropanol. The samples were 
swirled by hand until precipitation was complete. The DNA was recovered by lifting the 
aggregated precipitate from solution using a disposable yellow tip. Excess liquid is dabbed 
off and the DNA was dissolved in TE buffer (10 mM Tris.HCl, 0.1 mM EDTA, pH 7.5). 
The tube was then left overnight at 37°C to ensure the DNA was properly dissolved.
10.2.4 X-gal staining for (3-galactosidase activity
Staining of tissues, including ear punch, was done according to the method of Gossler and 
Zachgo (1993). Tissue samples to be stained were first of all fixed in fixative solution 
(0.2% glutaraldehyde in phosphate buffer containing 5mM EGTA and 2mM MgCl2) for 
30 to 120 minutes (depending on size) at room temperature. Very large tissue pieces were 
partially dissected to permit full penetration of reagent. The samples were then washed in 
three changes of washing solution (0.01% Na desoxycholate and 0.02% Nonidet P-40 in 
phosphate buffer containing 5mM EGTA and 2mM MgCl2) for 30 minutes each at room 
temperature. Then the samples were stained in staining solution (0.5 mg/ml X-gal, lOmM 
K3[Fe(CN)6] and lOmM K4[Fe(CN)6] in washing solution) overnight in the dark at 37°C. 
After staining the samples were washed in washing solution.
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The fixed and stained tissue samples were dehydrated, and embedded in paraffin wax. 
Sections about 10 pm thick were cut from the samples. Then the sections were dewaxed, 
mounted and visualised by microscopy.
Staining frozen sections is required when large tissues are to be analyzed. Frozen sections 
were cut by Iain McMillan in the Department of Pathology at Glasgow University 
Veterinary School. The procedure of staining was modified in the following ways: frozen 
sections about 10 pm thick were left to dry and firmly attach to glass slides that were 
gelatinized. Slides were fixed in fixative solution for 5 minutes at room temperature, 
washed three times in washing solution for 5 minutes each, and then stained in staining 
solution overnight (Histochemical staining trays are very convenient and allow easy 
handling of 20 slides at a time when two slides are put back to back). Then the slides 
were washed first for 5 minutes in washing solution, then 5 minutes in distilled water. 
After dehydrating sections in ethanol (70%, 96%, 100% EtOH, 5 minutes each), the slides 
were passed through xylene: EtOH 1:1 (1 minute) and xylene (1 minute), then mounted 
and visualised by microscopy.
10.2.5 Mutation frequency
By X-Gal staining, the cells having functional LacZ gene product, P-galactosidase, will be 
blue in colour. Any mutation affecting the enzymic activity of the P-galactosidase will 
turn the cells from blue to white. Thus, the mutation frequency in one tissue can be 
measured by screening sections of this tissue to count the fraction of colourless cells, i.e.
Number of colourless cells
Mutation frequency = -------------------------------------------------
Total cells
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From the published data, for one organ, at least 1 million cells should be counted. 
Therefore, if there are 100 cells in one microscopic field, at least 10000 fields should be 
screened.
10.3 Results
10.3.1 Breeding protocol
LacZ transgenic mice (ROSA mice) with a homozygous wild-type p53 gene have been 
available to us. It has been shown that, in this strain, LacZ is constitutively expressed 
(Figure 10.1). By crossbreeding with p53 knock-out mice, according to classic mouse 
genetics, we have been able to obtain LacZ transgenic mice having heterozygous wild-type 
p53 or homozygous p53 null backgrounds. It is however important to avoid having two 
copies of the LacZ gene. The breeding procedure is designed as follows: ROSA mice were 
mated with p53 null mice to produce a generation FI, then LacZ positive FI mice, which 
had one copy of the LacZ gene based on genetics, were backcrossed to p53 null mice or 
wild type mice (Figure 10.2). p53 genotype was determined by PCR (Figure 10.3 (A)), 
and LacZ genotype by staining of ear punch (Figure 10.3 (B)).
10.3.2 Staining
Staining of tissues is limited by the size of the specimen. Tissues tend to give staining 
problems due to impaired penetration of the substrate, despite attempts to cut them into 
very small pieces. Therefore, in these cases, staining of frozen sections is required.
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(C) (D)
Figure 10.1 Expression of  LacZ  gene in different tissues of  RO SA  mice. 
(A) Liver. (B) Kidney. (C) Spleen. (D) Skin. (E) Brain and (F) Intestine.
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Cross ROSA X p53(-/-)
I
Backcross : p53(+/+) X ROSA(+/-)/p53(+/-) X p53(-/-)
1  "  i
ROSA(+/-)/p53(+/+) ROSA(+/-)/p53(+/-)
ROS A(+/-)/p53 (+/ -) ROSA(+/-)/p53(-/-)
Figure 10.2 Experimental design of mouse breeding
The frozen sections of six tissues (skin, intestine, liver, kidney, spleen and brain) were 
stained. The results shows that the expression of LacZ gene in the FI backcross strain 
varied considerably in individual tissues and individual mice (Figure 10.4).
10.4 Discussion
The advantage of the new system (ROSA mice) to measure mutation in vivo is that almost 
all kinds of mutations (large or small deletions, point mutations etc.) should be detectable. 
The limitation of this new system is that it is only applicable to tissues where the 
expression of LacZ gene is uniform. Unfortunately, in our studies, after crossbreeding to 
p53 deficient mice, we found the expression of lacZ gene is highly non-uniform.
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(A) p53 genotyping by PCR
(B) L a c Z  genotyping by x-gal staining ear punch
Figure 10.3 Genotyping of p53 and L a c Z  gene. (A) p53 genotyping by PCR; 
(B) L a c Z  genotyping by x-gal staining ear punch
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Figure 10.4 Expression of LacZ  gene in different tissues of FI backciossing mice. 
(A) Liver, (B) Kidney. (C) Spleen. (D) Skin. (E) Brain. (F) Intestine, (G) Intestine. 
(H) Intestine and (I) Intestine. (A)-(F) obtained fromsame mice.
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The expression of LacZ gene in FI backcross strain varied in the tissues and mice possibly 
due to changing genetic background. In our studies, the genetic background of ROSA mice 
is C57BL/6J, whereas in p53 deficient mice it is 129/Sv. By crossbreeding two strains, FI 
mice contain 50% C57BL/6J genetic background and 50% 129/Sv genetic background. By 
backcrossing to p53 deficient mice, the backcross strain contains 25% C57BL/6J genetic 
background and 75% 129/Sv genetic background. The promoter of LacZ may be influenced 
by the genetic background, which leads to different expression. We have concluded that 
the ROSA mouse system holds promise for the future studies, but future studies to control 
genetic background and homogeneity of LacZ expression in tissue will be necessary before 
system is usable for its intended purpose.
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Chapter 11
Conclusions and Suggestions for Future Work
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11.1 Multistage models of tumorigenesis
11.1.1 Spontaneous tumorigenesis
The modelling work described here began with multistage models which provide a 
convenient conceptual framework within which to view the process of tumorigenesis. The 
initial studies focused on exploration of the effect of changing number of stages, mutation 
rate (in its most general sense), and ultimate (i.e. steady state) stem cell number on the 
timing of appearance of tumours. As expected, tumours tended to occur earlier with lesser 
stage number, higher stem cell number and higher mutation rate (Figure 11.1). However, 
a striking observation was that each of these dependencies was more pronounced at lower 
than higher mutation rate. With increasing mutation rate, the rate of growth of the earliest 
transformed cell exerted an increasing influence on tumour latency independently of the 
other variables.
The multistage models have been used to predict tumour multiplicity. In general, the mean 
number of tumours per mouse and its variation increases with decrease in the number of 
stages, and with increase in the mutation rate, and with increase in the stem cell number 
(Figure 11.1). The time lag between the first-appearing tumour and consequent tumours 
increases with increase in stage number and with decrease in the mutation rate.
With competing tumour development in two tissues showing different growth patterns, 
these modelling studies have shown that tumours tend to occur earlier in the tissues which 
show a sudden burst of growth in early life. The effect of alternative growth patterns on 
tumour spectra is also dependent on stage number and the mutation rate. With fewer stages
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and higher mutation rate, most of tumours will arise from the tissues which show a sudden 
burst of growth in early life. However, tumour spectra are also influenced by age. Tumours 
in the tissues which show a sudden burst of growth in early life are relatively over­
presented amongst early-occurring tumours.
Number o f mutational events 
for malignant transformation
Tumour latency ^  Tumour multiplicity ^Tumour incidence
Spontaneous mutation rate
J, Tumour multiplicity
of target cells ^Number
Tumour latency ^  Tumour multiplicity ^Tumour incidence
Figure 11.1 Influence of (A) the number of mutational events for malignant 
transformation, (B) the mutation rate, and (C) the number of target cells on tumour 
incidence, latency and multiplicity.
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11.1.2 Radiation tumorigenesis
With the incorporation of radiation effects, i.e. cell killing and mutation induction, into the 
multistage model, the modelling studies have shown that a single dose of radiation usually 
(but not always) results in the earlier appearance of tumours (see Table 4.1 and Table 6.2) 
and increases in tumour number per mouse (Table 6.1). Dose-latency and dose-tumour- 
multiplicity relationships are determined by stage number, the spontaneous mutation rate, 
and age at exposure. Dose-latency findings may be grouped into three categories of 
relationship:
(1) The T50 (i.e. time until tumours are detected in 50% of the mice) decreases with 
increasing dose down to a minimum, with an increase following that minimum (most 
instances);
(2) T50 is flat with increasing dose;
(3) T50 increases with dose.
The dose-tumour-multiplicity relationship seems follows a constant pattern - the mean 
number of tumours per mouse increases with increasing dose up to maximum, followed 
by decrease. However, the shape of both the dose-latency and the dose-tumour relationship 
curves are determined by stage number, the spontaneous mutation rate at each stage, and 
age at exposure.
11.2 Multipath multistage models of tumorigenesis
The present studies have shown that tumour development from any route is dependent on 
the number of mutational events required for malignant transformation and mutation rate
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in this route.
11.3 Multigate/multistage models of tumorigenesis
Much biological evidence exists indicating that tumours arise and progress through the 
accumulation of various genetic mutations. We have proposed that there are at least two 
types of mutations, i.e. directly tumorigenic mutations and indirectly tumorigenic 
mutations. We have also proposed a multigate/multistage model, which specifies that 
tumorigenesis requires a number of regulatory 'gates' to be passed, and a tumorigenic 
mutation of direct type alters a gateway gene and corresponds to a gate-pass event. 
However, indirect mutations are not enabling events in themselves but modifiers of the 
tumorigenic mutation rate. An important feature of these models is that mutation of the 
gateway genes alone (without modifier gene mutations) may lead to malignant 
transformation, whereas modifier mutations cannot achieve transformation without gate- 
pass events.
The present studies have shown that tumour incidence, latency and multiplicity are 
dependent on the number of gates required for malignant transformation and stages 
required for the rate-modifier process, the mutation rate of the gate-pass and modifier 
genes, and the rate-modifier factor (Figure 11.2).
The proportion of tumours arising by gate-pass mutations plus rate-modifier gene mutations 
increases with age, which implies that the tumours with modifier mutations will be 
relatively over-represented amongst late-occurring tumours. However, this relationship is
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influenced by the number of gates and stages, the rate of the gate-pass and modifier 
mutations, and the rate-modifier factor.
It has been shown that tumours arising by gate-pass mutations only occur slightly earlier 
than those by the gate-pass plus modifier mutations, this difference is also dependent on 
the number of gates and stages, the rate of the gate-pass and modifier mutations, and the 
rate-modifier factor.
(A)
Number of gates for malignant 
transformation
T\imour multiplicityTumour latencyTumour incidence
(B) Number of stages for I 
rate-modifier process ▼
Tumour multiplicityTumour latencyTumour incidence
(C) Gate-pass mutation rate
Ttimour incidence ^  Tumour latency ^  Tumour multiplicity ^
(Figure 11.2 to be continued)
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(D) Modifier mutation rate
Tumour latency 1  Tumour multiplicity jTumour incidence
(E) Rate-modifier factor
J, Tumour multiplicity ^Tumour latency
Figure 11.2 Influence of parameters in the multigate/multistage model on tumour 
incidence, latency and multiplicity.
11.4 Interpretation of the role of p53 in tumorigenesis
These modelling studies have demonstrated a fundamental problem in the application of 
the classic multistage model to spontaneous and radiation-induced tumorigenesis in p53 
deficient mice. The single pathway multistage models in which inactivation of each p53 
allele represents a distinct stage predict excessively large numbers of tumours in both p53 
heterozygotes and p53 null homozygotes. The analysis shows that this prediction applies 
for up to five stages being required for tumorigenesis in wild type mice and allow this 
category of models to be rejected.
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Our analysis has identified two categories of explanation for Vogelstein's paradox, i.e. the 
unexpectedly small number of tumours developing in p53 deficient mice and in Li- 
Fraumeni patients inheriting defective p53 alleles (Vogelstein, 1990). The first of these, 
the multistage multipath model invokes a p53 independent pathway which exists in parallel 
with a p53 mediated route of tumorigenesis. Only the latter route is enhanced in p53 
deficient genotypes. On this type of model, the mutation rates are independently fixed and 
these inherent rates are not changed by p53 inactivation. We have found that a p53 
mediated 5-stage pathway which provides 20% of the tumours in wild type mice is 
consistent with the data.
The second mechanism, which we have called the multigate model postulates a single 
pathway (or gateway) with several gate-pass events (obligatory mutations) occurring at a 
rate which depends on p53 status. We have observed that the data can be accommodated 
by a 2- or 3-gate model in which the gate-pass mutation rate is amplified by a factor of 
about 10 when both p53 alleles are inactivated. From simulations to date 2-gate model 
seems better than the 3-gate model, but further evidence is required.
11.5 Future studies
11.5.1 Multigate/multistage model
The bulk of the work to date has been on spontaneous tumorigenesis and has involved 
exploration of the effect of the various parameters in the multigate/multistage model on 
tumour incidence, latency and multiplicity. We will extend this analysis to radiation-
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induced tumorigenesis in p53 deficient mice, for which some experimental data has already 
been reported (Kemp et al., 1994). We expect that stochastic modelling of tumorigenesis 
in p53 deficient mice will contribute to an understanding of tumorigenesis in human Li- 
Fraumeni patients as well as to the role of p53 in human cancer more generally.
11.5.2 Analysis of tumorigenic data in other transgenic mice
The approach taken in our studies should also prove useful for analysis of tumorigenesis 
in other transgenic mouse models, such as Rb, Ras etc transgenic mice, especially where, 
as in the MSH2 deficient (mismatch repair deficient) transgenic model (Reitmar et al, 
1995) the genetic defect would be expected to act as a modifier of putative gate-pass 
events. It is expected that these studies should make a substantive contribution to the 
understanding of the role of cancer genes in tumorigenesis.
11.5.3 Analysis of human tumorigenic data
The stochastic models of tumorigenesis which are developed in the present studies can be 
applicable to study tumorigenesis in human, especially inherited human cancers, such as 
Li-Fraumeni patients. We will undertake this analysis using available Li-Fraumeni data in 
future.
11.5.4 Experimental studies
We have observed that variability of LacZ gene expression makes the ROSA/p53 deficient 
mice unsuitable for in vivo evaluation of the altered mutation rate hypothesised to be 
caused by p53 inactivation. It is necessary to find a new mutation detection system and
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compare the mutation frequency in mice of different p53 background. Until then, the 
modelling studies and in vitro studies (with somewhat conflicting data) provide the only 
available of the effect of p53 inactivation on mutation rate.
11.6 Conclusions
In conclusion, these studies have shown the complex relationships which exist between 
mutation rate, tumorigenic stage number and tumour latency and multiplicity in 
spontaneous tumorigenesis and radiation-induced tumorigenesis. Dose-response 
relationships are not necessarily simple and experimental or epidemiological observations 
may need to be interpreted using appropriate models. We have shown that the classical 
multistage model cannot explain tumorigenesis data in p53 deficient mice and have 
proposed alternative models for this. The multigate/multistage model has been developed 
mathematically for the first time. Some predictions of the model (eg magnitude of the 
modifying factor, age-incidence of p53-mediated and non-p53-mediated tumours) should 
be experimentally testable. Some other predictions, on the relationship between the number 
of target cells and tumour multiplicity, on the effect of prenatal and post-natal irradiation 
on tumour latency, should also be experimentally testable. It is hoped that some of the 
methods developed here will be applicable to tumour development in other mouse models, 
and ultimately to human cancer.
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Appendix 1
Mathematical Development of the Multistage Model of Tumorigenesis
The model of tumorigenesis, as illustrated in Chapter 5, is a k-stage model of 
tumorigenesis with growth and differentiation of all cell types. Let X0(t), X^t), X ^ t) ,
Xk(t) and T(t) represent the number of stem cells, 1-stage mutants, ..., k-l-stage mutants, 
tumour cells arising from stem cells and tumours by time t, respectively. At time t=0, 
X0(0)=Xo, Xj(t)=0, (j=l, 2, ..., k), and T(0)=0. In a small time interval [t, t + A t ] ,  a j-stage 
mutant may
(1) divide into two j-stage mutants at rate b j ( t ) A t + o ( A t ) ;
(2) die (or differentiate) at rate d j ( t ) A t + o ( A t ) ;
(3) divide into one j-stage mutant and one j+l-stage mutant at rate pjAt+o(At). j=0,l, ...,k-l 
where a 0-stage mutant is a stem cell and a k-stage mutant is a tumour cell; or
(4) stay unchanged.
All cells go through the above processes independently of other cells.
1.1 The expected number of cells of each type
Let ^(Sq, s1? ..., s*.; t) be the probability generating function (PGF) of Xj(t), j=0, 1, ..., k. 
The Kolmogorov forward equation for T^Sq, slf ..., sk; t) is (Tan, 1991, chapter 6)
aT (j0,s.'0» l»w *
dt
-  [b p ) +  d p )  +
(A l.l)
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according to the definition of PGF, obtaining
d s j
From (A 1.1) and (A 1.2), we obtain
d E X p )
dt
= [b0( t ) - d 0(t)]EXa(t)
dEX(t )
— ± 1  + 0 = 1 ,2 ,. . . ,* - l)
dEXit)
so that,
E X 0( t )  - e -
t
' UbjW-djWds
EXp) = I ny EXj4( t )  e-  dx 0=1,2.....kA)
E X p )  = ( ^EXt4(r)dr
0
1.2 The expected number of tumours
The expected number of tumours by time t, ET(t), is
E T ( t )  = J f d ( u , t )  ]ikEXkp u ) d u
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(A 1.2)
(A1.3)
(A1.4)
(A1.6)
where FD(u,t) is the probability that a tumour cell at time u is detectable as a tumour by 
time t (see Tan, 1991, p60-61).
Proof. To prove the above equation (A1.6), partition the time interval [0, t] by Ij=[tj_1, tj), 
j= l, n-1, and tn], where tj = j A t and n A t = t  with tn = t .  Let Mj be the number of
tumour cells generated from normal stem cells during the time interval Ij5 Mj = Xk(tj)-Xk(tj. 
,), j=T, ..., n. Then the expectation number of the tumours formed from these Mj tumour 
cells is MjF(tj,t). Taking the expectation over Mj, we obtain [EXk(tj)-EXk(tj.1)]F(tj,t), so that
ET( t )  = l im £  [EX. i t . ) - E X k(t^  ) ]F D(r„t)
it-* 0 j  =i
" \EX.( t . ) -EXAt_, )]
-  I im £  — ^ ------t- ^ - F D ( t.,t) *
it-*0 j  =j At
(A1.7)
dEXAu)
= f -  -FD{u, t )du  
a uo
t
= lFD(u, t )dEXk(u)
From (A1.3), we can obtain
ET(t)  = f \ikEXk4(u)FD(u,t)du
In practice, it is very difficult or impossible to compute exactly the incidence rate of 
tumours, the expected number of cells of each type and the expected number of tumours, 
especially when the number of stages is greater than 2. However, computer simulation 
provides a very powerful tool. Thus, in our studies, computer simulations have been used 
to explore the properties of the various models that we considered (see appendix 3).
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Appendix 2
Mathematical Development of the 3-gate/2-stage Model of
Tumorigenesis
The model of tumorigenesis, described in Chapter 8 (Figure 8.2), is a 3-gate/2-stage model. 
Let X01(t), X02(t), X03(t), X„(t), X12(t), X13(t), X2](t), X22(t), X23(t) and Y(t) represent the 
numbers of stem cells with p53+/+ (S/p53+/+), stem cells with p53+/' (S/p53+/'), stem cells 
with p53'/‘ (S/p53'/‘), gate-1 mutants with p53+/+ (Gl/p53+/+), gate-1 mutants with p53+/‘ 
(Gl/p53+/‘), gate-1 mutants with p53‘/_ (Gl/p53'A), gate-2 mutants with p53+/+ (G2/p53+/+), 
gate-2 mutants with p53+/* (G2/p53+/'), gate-2 mutants with p53'/_ (G2/P53'7'), and malignant 
cells generated from stem cells by time t, respectively. At time t=0, X01(t)=l, X02(t)=0, 
X03(t)=0, Xn(t)=0, X12(t)=0, X13(t)=0, X21(t)=0, X22(t)=0, X23(t)=0 and Y(t)=0. In a small 
time interval [t, t+At), the probability of each event happening is shown in Table A2.1. The 
probability of more than one event is o(At), defined such that: lim[o(At)/At] = 0 as At 
approaches 0.
2.1 The expected number of cells of each type
One focus of interest in tumorigenesis lies in investigating the expected number of cells 
in each stage. The Kolmogorov forward equations provide a means for calculating these. 
Let Pt(ij, i2, i3, j 1? j2, j 3, ll5 12, 13, k) = Pr{ X01(t)=i!, X02(t)=i2, X03(t)=i3, X ^ t ) ^ ,  X12(t)—j2, 
Xi3(t)=j3, X21(t)=l], X22(t)=l2, X23(t)=l3,Y(t)=k}. The Kolmogorov forward equations yield 
the partial differential equation:
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Table A2.1 Transitions and transition probabilities of the multigate process for 
tumorigenesis
Parent at t Progenies at t+ A t Probabilities
1 S/p53+/+ cell 2 S/p53+/+ cells b 0 At +  o(A t)
1 S/p53+/+ and 1 G l/p53+/+ cell P i At +  o(A t)
1 S/p53+/+ and 1 S/p53+/‘ cell At +  o(A t)
differentiation/death cell <io At +  o(A t)
1 S/p53+/- cell 2 S/p53+/* cells b 0 At +  o(A t)
1 S/p53+A and 1 G l/p53+/‘ cell P i At +  o(A t)
1 S/p53+/' and 1 S/p53-A cell /u At +  o(A t)
differentiation/death cell do At +  o(A t)
1 S/p53-'- cell 2 S/p53'/_ cells b 0 At +  o(A t)
1 S/p53-/’ and 1 Gl/p53-A cell k p At +  o(A t)
differentiation/death cell do O
+
1 G l/p53+/+ cell 2 G l/p53+* cells b , At +  o(A t)
1 G l/p53+/+ and 1 G2/p53+/+ cell P : At +  o(A t)
1 G l/p53+/+ and 1 G l/p53+/’ cell /v-l At +  o(A t)
ldifferentiation/death cell d, At +  o(A t)
1 G l/p53+/- cell 2 G l/p53+/' cells b i At +  o(A t)
1 G l/p53+/’ and 1 G2/p53+/‘ cell u 2 At +  o(A t)
1 G l/p53+/‘ and 1 G l/pSS^ cell *2 At +  o(A t)
differentiation/death cell d, At +  o(A t)
1 G l/p53v* cell 2 G l/p53v' cells b i At +  o(A t)
1 G l/p53v‘ and 1 G2/p53'/’ cell k p At +  o(A t)
differentiation/death cell d, At +  o(A t)
1 G2/p53+/+ cell 2 G2/p53+/+ cells b 2 At +  o(A t)
1 G2/p53+/+ and 1 malignant cell P j At +  o(A t)
1 G2/p53+/+ and 1 G2/p53+/’ cell A,( At +  o(A t)
differentiation/death cell At +  o(A t)
1 G2/p53+/' cell 2 G2/p53+/- cells b . At +  o(A t)
1 G2/p53+/‘ and 1 malignant cell P j At +  o(A t)
1 G2/p53+/- and 1 G2/p53v‘ cell /u At +  o(A t)
differentiation/death cell d2 At +  o(A t)
1 G2/p53'/- cell 2 G2/p53v- cells b 2 At +  o(A t)
1 G2/p53_/' and 1 malignant cell k p At +  o(A t)
differentiation/death cell d. At +  o(A t)
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^ ^ +^  + b f i)+ ^ (t)] + ^ +^ + ^ +^ (t)] + fj^ +^ +dJM
d t
*J\ [P i* + *i(0 + d\(f)l+J'zCP- + ^ z + b\&  + rfiC01 +J\[kV-z + 61(0 + ^ (OJ
+ / t [ j i ,  +  a .1 +  6,(0  +  ifz(r)] +  L ( p 2 +  A., +  6,(0  +  <i,(0 ]
+ lz [fcu, + 6,(0 +  <f,(0 ] ^ , 0' t , J ,  J 2 J , , / , ,  lv L ,k)
+ 0 \  -  l ^ o i ^ o y - 1 j zj \ , i xj zj z,k)
"* 0\ + 0 dgfflPt(j\ + 1 »L,Z3 »/1 dz^Z ’ A ’ Z^’ 3^
"r  [ 0 ' 2 “  0  ^ o ( 0  +  *1 ^*1 ] - P , 0 ' ,  » ^ 2  ”  ^ ,Z 3 « A  d z d i  » ^ i  *^z*^Z ’ k ^
■*" 0 \  +  i )  ^(jC O ^1(f\ >^z "**  ^»Z"j */i ’^l ’ ^2*^ 3
+ [ ( / ,  -  1) 60(0 +  i2A .,] i’f(/l , 1 j \ j \ j \ J xJ zJ.,k)
“ Oj + 0 t (*'j, /,, ■*■ l »y i >y2 v/3 * ^ »^2»^2 >^0
+ [0\ - iWO + h P j^ C v V ,,/ , - 1 ^Wj 'V 'v 'v^
- C/\ + 1 ) ^ ( 0 ^ , I J n J i . l x A J ^ k )
“ [ ( / ,  — I)  6 f( 0  ■*' *2 P i +7i ,Z; ,Z3 I dz ~~ 1 diJ^Jzikyk)
* 0 2 "’’ O ^jCO ^3,0 j  »L »Z3 >^ l v/’ +  ^v/j »^2’ 3^
■>■[(/, -  l ) 6l (r) + »3A:pl + y2X , ] i , / 0\ , / 2,x3Il; ,l J , j j -  l f / . , / 5f /j ,A )
+ 0 j+1)^ (0 ^ , 0\»L • *3 *A */’ ••/ j +1 J^Jz’h ’k) (A2.1)
+ [(/, - 1)6.(0■+*y\p:]^,0\>*2»h*A«A«A»A “ UL.L.i)
+ (/j + l W O - ^ A , L  • *j J\ J'z >J\ J x ^ J Z. lz ’k)
* [(/: - 1)6:(0 +y2p2+i1A.l]pf(il,/z,/3 j ,  j z,jz,ix,L- 1 ,/,,*)
+ ( / ,  +  j \  j i J v h * l z +  1 , / , , * )
+ [ ( / .  -  1) 6 , ( 0  + / ,  k  u ,  +  / : ^ 2  ] (*1»Z;  ’ Z3
+ ( / ,  +  t )  ^ ; ( 0 ^ , 0 \  . ^2 > ^  J\ J'z J\  J :J zJ z+t  ,k)
"r  [^i P3 + ’^ P3 +  ^3^“ 1 *Jz v/3 »^l »'^2»^3
Let G(slf s,, s3, zt, z., Z3, rt, r2, r3, y; t) be the joint probability generating function of 
Xoi(t), Xo2(t), ^ ( t ) ,  Xu(t), Xl2(t), Xl3(t), X21(t), X ^ t), Xa(t) and Y(t) given the initial 
conditions. From (A2.1),
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From (A2.2), we can obtain the expected number of cells of each type, 
f dE X0l(t)
dt  =[60(O -rf„(O ]5X ol(O 
ft)
= [b0( t ) -d 0(t)]EX02(t) + X,EX0l(t)
d E X02(
dt
( t )
- [ 6 o(O -rfo( O ] ^ , ( O + ^ OJ(0
dEX03
dt
d E X J t )  ("A2 3)
' ,W  =[bj { t ) - d j (t)}EX.l { t ) * V.jEXJAX(t)  0 = 1 ,2 )
dt
^  = [ * ( 0 - r f ( 0 ] ^ 2( 0 ^ / ^ 2( /)+ x 1£ x ;,(0  0 = 1 ,2 )
( t )
= [A O) - d (t)]EX.3(t) + k ^ . E X ^ f t ) * X 2EX (t) 0  =1,2)
dEXj2(t) 
it
dEX.3
dt
= ^ E X J t )  + ^ E X J t )  + k ^ E X J t )
at
2.2 The expected number of tumours
Let T(t) represent the number of tumours occurring by time t. Thus, the expected number 
of tumours, ET(t), is
t
ET ( t )  = fFDf u , t) {^3£X21(m)+ (i3£X22(«)+ k ^ E X ^ d u  (A2.4)
0
where FD(u,t) is the probability that a tumour cell at time u is detectable as a tumour by 
time t. The proof is similar to that shown in appendix 1.
In practice, it is also very difficult to compute the incidence rate of tumours, the expected
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number of cells of each type and the expected number of tumours, specially when the 
number of gates is greater than 2. Here too, the computer simulation provides a very 
powerful tool, and has been used to explore the properties of these models.
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Appendix 3
A General Flow Chart of the Computer Simulation for Tumorigenesis 
Models ______
_____________________ y_____________________
/Set  up and read the value of parameters in the 
/  model and the number of repeats of simulation
Y
Initialize tum origenesis 
process, i.e., only 1 normal 
stem cell at t=0
Update the clock one cell cycle time
v
Revise process to reflect all 
changes that have occured in 
this time interval, i.e., simulate 
what has happened to each 
cell of each type during one 
cell cycle time
Update the number of cells of each /  
type, tumour cells, and tumours /->
No
Has 
the age of 
mouse reached 
600 days ?
If one new tumour cell is 
genera ted  from  stem  
cells, this tumour cell will 
b e  i n d i v i d u a l l y  
fo llo w ed -u p  to  find  
w hether it becomes a 
tumour or not by the end 
of 600 days.
Output the time of the first ten tumours, 
the number of tumour cells generated 
from stem cells, and the number of 
tumours
1
End
243
Stochastic simulation process shown above can be described as the time-slice approach, 
in which the tumorigenic process is viewed as changing in all of its aspects over time. Its 
status is updated, in units of one cell cycle time, until a prescribed amount of time has 
elapsed. In our studies, we suppose the cell cycle time is not influenced by the mutional 
events.
In each cell division, cellular behaviour is as described in Chapter 3. For normal stem cells 
and mutants, the distribution of the number of cells was computed without following the 
fate of every cell: homogeneous patches of normal stem cells or mutants were treated as 
groups. For such groups only the number of cells were updated, using a multinomial 
random number generator, but using Poisson and normal random number generators to 
provide approximation when the number of cells is very large. Malignant cells arisen from 
normal stem cell are followed individually. All computer programs were coded in 
FORTRAN which can be excuted in DOS and in Unix systems.
The method for estimating the parameters in the models, which involves matching the 
tumour-free survival distribution of the experimental data with simulated data by a Monte 
Carlo method, is as follows: Partion the time interval [0, t] by Ij=[tj_ls tj), j= l, ..., m-1, and 
Im=[tm_], tm], where tj =j*At and m*At=t with t=tm. Let Nj and nj be the number of mice that 
acquired tumour during Ij for the simulated and experimental data respectively. The 
parameters are estimated by minimizing the chi-square statistic:
(A3)
In our studies, At=7 days, m=86.
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